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Abstract
Inorganic nanoparticles and their accompanying diverse physical properties are now virtually in
routine use as imaging tools in cell-biology. In addition to serving as excellent contrast agents,
their size- and environment-dependent optical and magnetic properties can be harnessed to
create enzyme biosensor devices of extremely high sensitivity, whilst circumventing the numerous
technical limitations associated with traditional enzyme assays.
This thesis explores new applications of noble metal and semiconductor nanoparticles (quan-
tum dots) for the detection of a range of medically-relevant enzymes. Here, water soluble col-
loidal gold nanoparticles and quantum dots are modiﬁed with peptides and antibodies to aﬀord
new reagents for enzyme sensing. These bio-functionalised nanoparticle probes exhibit numer-
ous advantages over traditional enzyme sensing systems owing to their robust and size-tuneable
optical properties.
These enzyme-responsive nanoparticle systems are tailored to detect the activity of protein
kinase and histone acetyltransferase activity in a simple homogeneous assay format based on
Förster resonance energy transfer (FRET). Furthermore, these systems can be applied to screen
for putative small-molecule modulators of enzyme function. These new assays should provide the
basis for the development of a variety of new enzyme detection strategies based on nanoparticle-
speciﬁc optical phenomena.
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Chapter 1
Introduction
1.1 Introduction
Nanobiotechnology, in its broadest sense, seeks to develop novel approaches for the treatment,
imaging and diagnosis of disease or to create new tools to interrogate fundamental biologi-
cal processes by exploiting unique phenomena associated with nanoscale biological materials
and nanoscale bioconjugates. The ability to address such important biological problems from a
nanotechnology-enabled angle often by necessity requires adopting a cross-disciplinary approach,
incorporating elements of biochemistry, molecular biology, medicine, chemistry, materials sci-
ence, solid-state physics and spectroscopy. For example, as a good illustration of the poten-
tial power arising from such successful integration of disciplines, highly elaborate biomolecule-
nanoparticle formulations can be developed which are capable of simultaneous targeted drug-
delivery to and multimodal magnetic/ﬂuorescence imaging of tumours in live mice [15]. The
ability to provide such unrivalled imaging potential is aﬀorded by the use of metallic and semi-
conductor nanoscale materials which posses unique and fascinating properties.
When the dimensions of many materials are reduced to the nanometer scale, new proper-
ties unseen in the bulk material often become apparent. For instance, novel electronic, optical,
magnetic and mechanical properties emerge in materials on the nanometer size regime. Nan-
otechnology aims to integrate these unique nanoscale phenomena into functional devices. For
example, the size-tuneable band-gap of semiconductor nanocrystals provides a means to create
16
eﬃcient and cost-eﬀective photovoltaic cells and light emitting diodes [16]; the high extinction
coeﬃcients and plasmonic optical properties exhibited by noble metal nanoparticles allows them
to serve as powerful biological detection reagents; magnetic nanoparticles can enable ultra high-
density data storage devices [17] and carbon nanotubes can be incorpoprated into composite
materials to confer remarkable mechanical properties [18].
The ability to speciﬁcally tailor the surface chemistry of many of these nanomaterials and
functionalise with a diverse range of biological molecules allows the realisation of hybrid mate-
rials, combining nanomaterial-speciﬁc properties with environment-responsive and speciﬁc bio-
recognition motifs. This provides new materials with powerful applications to in vitro and in
vivo imaging, drug delivery, diagnostics and advanced therapeutic strategies [2]. A notable area
where nanomaterials show great potential is the ﬁeld of enzyme sensing and assay development.
The sophisticated chemical transformations and cellular signaling events that occur in in-
side living cells are mediated by a host of enzymes. Enzyme dysfunction or aberrant activity
is often manifested in the development of disease states and as such much attention has been
centred upon the development of small molecule-modulators of enzyme actvity. This requires
the ability to quantitatively measure enzyme activity and is routinely carried out using ﬂuores-
cence, radioisotope labeling or immunological methods [19]. Nanoparticles oﬀer several notable
advantages compared to these traditional approaches owing to their unique photophysical and
optical properties. For instance, they can serve as eﬃcacious alternatives to ﬂuorescent dyes due
to their strong resilience to photobleaching and potential to selectively tune desired emission
wavelengths to match the requirements of the assay. For example, quantum dots can be tailored
to emit in the far-red region of the spectrum, where biological autoﬂuorescence - a common
source of signal interference in enzyme assays - is at a minimum, [20] and nanoparticle-based
approaches in general abrogate the need for potentially hazardous radiolabeled tracers. In con-
sideration of the numerous potential beneﬁts of using nanoparticles in enzyme-detection, this
thesis aims to develop new approaches to enzyme detection.
1.1.1 Scope of the thesis
This thesis explores the use of biologically-modiﬁed semiconductor quantum dots (QDs) and
gold nanoparticles (AuNPs) to devise novel approaches to enzyme sensing through utilisation of
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their unique plasmonic and photoluminescent properties. These new enzyme assays are demon-
strated to have persuasive advantages over currently used methods and have potential utility in
high-throughput drug screening applications. The focus of this thesis is centred upon two per-
tinent enzyme systems implicated in the development of numerous pathological conditions such
as cancer; namely protein kinases and histone acetyl transferases. Protein kinases are an ubiq-
uitous family of enzymes which catalyze phosphate transfer from adenosine triphosphate (ATP)
to the hydroxyl terminated side chains of serine, threonine and tyrosine amino acid side chains.
Kinases play a prominent role in regulation of cell-signalling cell-cycle progression and are con-
sidered to be excellent targets for pharmaceutical intervention [21]. The second enzyme family
interrogated using nanoparticle-based approaches are the histone acetyl transferases (HATs).
These enzymes selectively modify key amino acid residues of an evolutionarily conserved fam-
ily of proteins involved in condensation of the genome within the nucleus, preservation of the
genome integrity and regulation of fundamental aspects of gene regulation. HATs catalyse the
acetylation of conserved lysine residues found within histone proteins serving to provide post-
translational markers which recruit further eﬀectors of DNA metabolism [22]. The ability of
HATs to inﬂuence the activation of cancer-potentiating genes (oncogenes) has lead to the sug-
gestion that speciﬁc small-molecule inhibitors may have therapeutic potential [23]. Chapter 1
provides an overview of the optical properties of quantum dots and gold nanoparticles, represen-
tative examples their use in bio-sensing and current commonly used methods to detect enzyme
activity. Chapter 2 describes initial eﬀorts to devise a colourimetric gold nanoparticle-based
sensing system for protein kinases in which antibody-modiﬁed gold nanoparticles are designed
to undergo aggregation in a enzyme-dependent manner. Chapters 3 and 4 concern the devel-
opment of an alternative energy-transfer approach based on the use of QD-peptide conjuates.
As a necessary step to realise this goal, Chapter 3 details the conjugation of QDs to synthetic
peptide substrates for protein kinases and further characterisation using gel electrophoresis and
time resolved photoluminescence. Following from these results, Chapter 4 demonstrates the
utility of these QD-peptide conjugates as surrogate protein kinase substrates that can be used
in a new enzyme assay based on Förster resonance energy transfer (FRET). Further evidence
suggests that this assay may have utility as a drug discovery tool using a model small molecule
protein kinase inhibitor. Chapter 5 extends from this kinase assay principle to demonstrate that
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it can be readily tailored to detect the activity of other enzymes, as illustrated with applica-
tion to histone acetyl transferases. This suggests that the enzyme sensing strategies developed
here provide a generic platform for the detection of diverse and functionally unrelated enzymes,
providing a potentially valuable addition to the enzymology and drug-discovery toolbox.
1.2 Quantum Dots
1.2.1 Structure, synthesis and optical properties
Quantum dots (QDs) are crystalline semiconductor materials, typically of dimensions nanome-
ters to tens of nanometers which exhibit optical and electronic properties governed by their
size, composition and morphology. As such, they are considered to be powerful materials for
the construction of high-eﬃciency solar cells and light emitting devices [24]. Furthermore, their
robust photoluminescent properties, resistance to photobleaching, chemical stability, large ef-
fective Stokes shift and narrow tuneable emission allow them to serve as powerful alternatives
to ﬂuorescent dyes used routinely in biological imaging [25]. Figure 1.2 presents a representa-
tive high resolution TEM image of an individual quantum dot and illustrates their nanoscale
dimensions and crystalline structure.
QDs typically consist of elements from periodic groups II-VI or III-V (e.g. CdSe, CdTe,
InP, InAs), although more complex alloyed formulations exist [26]. They are often prepared
by means of rapid injection of organometallic precursors into a high-boiling and coordinating
solvent, resulting in rapid and homogeneous particle nucleation, followed by a slower growth
period, yielding high-quality particles of narrow size-dispersion [27] [28]. Furthermore, a second
lattice-matched inorganic shell of a higher band-gap material is often grown epitaxally upon the
as-formed particle to form core-shell structures, so as to passivate non-radiative recombination
sites arising from surface defects, shield the core from photooxidation and improve quantum
yields [29]. Alternative methods of synthesis have been devised which greatly improve upon
the scalability of QD synthesis by employing preformed molecular clusters which serve as sites
for homogeneous nanocrystal nucleation. The distinct separation of nucleation and growth
aﬀords high control of nanocrystal size and polydispersity and obviates the need for hazardous
or pyrophoric precursors [30].
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QDs exhibit an electronic band structure intermediate between that of bulk semiconductors
and atomic systems, with the band gap energy, Eg , determined by the size of the nanocrystal as
its dimensions become of the same order as the size of the Bohr exciton radius [31]. These size-
dependent electronic properties are analagous to particle-in-a-box-like quantisation of energy
levels. Conﬁnement of the electron and hole pair wavefunctions within a potential well results
in the valence and conduction bands of the material no longer forming continuous energy bands,
but discrete energy levels, with the band gap separation increasing as the particle size decreases
(Figure 1.1). For example, in the simple case of modeling a quantum dot as a box of dimensions
lx,ly, lz, the energy levels of electrons in such a system take speciﬁc values, given by
En =
h2
8me
[(
nx
lx
)2
+
(
ny
ly
)2
+
(
nz
lz
)2]
where the principal quantum numbers, nx,ny,nz take integral values (1, 2, 3...) leading to
the density of electron states adopting a series of δ−functions (i.e. discrete energies). In the
case of idealised spherical nanocrystalline semiconductors of radius R, where the electron and
hole wavefunctions must satisfy the boundary conditions of ψ(r ≥ R) = 0, Brus demonstrated
that in the case of CdE (E=S or Se), the energy of the lowest energy transition, ∆E, can be
approximated by:
∆E = Eg +
~2pi2
2R2
(
1
me
+
1
mh
)
− 1.8e
2
4piεε0R
where Eg is the band gap of the bulk material, me and mh are the electron and hole eﬀective
masses, e is the electron charge and ε and ε0 are the relative permitivities and permitivity of
free space respectively [32] . The ﬁrst term is the band gap of the bulk material, the second term
describes quantum conﬁnement eﬀects and the third term accounts for electron-hole Coulombic
interaction which lower the energy of the ﬁrst electronic transition and becomes increasingly
important in weaker conﬁnement regimes, where the radius of the QD becomes larger than the
Bohr exciton radius [31].
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Figure 1.2: High resolution TEM image of commercially available CdSe/ZnS nanocrystal (605
nm emission maximum) - courtesy of Mr John Dick, Imperial College, London
Figure 1.1: Density of states for bulk, nanocrystal,atomic systems and for diﬀerent quantum
conﬁnement regimes [1]
Following electrical or photoexcitation and picosecond non-radiative relaxation to the lowest
excited state, radiative recombination of the created electron-hole pair occurs on the nanosecond
timescale and results in the emission of a photon of wavelength proportional to the bandgap
energy [1]. The size-tuneable band gap provides a convenient means to selectively tailor QD
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Figure 1.3: Size- and material composition-dependent tunability of semiconductor nanocrystal
photoluminescent emission spectra from the visible to infra-red. Adapted from [2]
absorption and photoluminescence emission characteristics across the visible spectrum to suit
the particular application (Figure 1.3), leading to appreciable utility in biological imaging and
sensing applications [25]. Quantum dots have several other important advantages compared to
organic ﬂuorophores due to their strong resilience to photobleaching, allowing for long observa-
tion times on the order of several hours using standard ﬂuorescence microscopy techniques [33].
Also, the relatively long excited state lifetime preceding electron-hole radiative recombination
compared to biological ﬂuorophores also provides a convenient means to reject interference from
background autoﬂuorescence using time-gated detection, greatly improving signal:background
[34].
1.2.2 Water soluble quantum dots for biological applications
Although QDs can be prepared directly in aqueous solution (e.g. CdTe, CdSe) [35][36], high-
quality and bright QDs of narrow size distribution are typically prepared in organic solvents, and
their surface coating (capping agent) results in solubility restricted to non-polar organic solvents.
Thus for biological applications, a range of phase-transfer procedures have been developed,
including ligand-exchange with hydrophilic thiols and peptides or encapsulation withing micelles,
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oligomeric phosphines, silica shells or amphiphilic polymers [37] [25][38]. Depending on the
synthetic route chosen, the absorbance proﬁle, photoluminescence quantum yield, hydrodynamic
dynamic radius and colloidal stability of the QD can often be substantially altered during phase
transfer procedures [37]. Furthermore, the solubilisation strategies vary in their requirements for
synthetic expertise and ease of puriﬁcation. The choice of the solubilisation method employed is
largely determined on the intended ﬁnal application. For example, whilst a polyethylene glycol-
based triblock copolymer QD coating could provide enhanced colloidal stability and reduced
non-speciﬁc binding in the context of in vivo imaging [39], the increased hydrodynamic radius
of the complex due to the polymer layer could hinder its applicability to energy-transfer based
sensing [40]. Water soluble QDs of substantially smaller hydrodynamic radius can be prepared
through thiol based ligand exchange, however such approaches often suﬀer from substantially
diminished quantum yields, poor colloidal stability in low pH or high ionic strength media and
are susceptible to ligand dissociation [37]. Multidentate thiols, such as dihydrolipoic acid, on the
other hand, can impart greater colloidal stability owing to a lower propensity to dissociate from
the QD surface and can be further derivitised with functionalised oligoethylene glycol groups for
reduced non-speciﬁc binding in protein-rich media and to provide additional chemical handles
(NH2, COOH) for further modiﬁcation [41].
1.2.3 Quantum Dots and Energy Transfer
1.2.3.1 FRET background
Förster resonance energy transfer (FRET) is the distance-dependent non-radiative energy trans-
fer between an excited state donor (D) ﬂuorophore and ground state acceptor (A). This phenom-
ena occurs due to dipole-dipole interactions between ﬂuorophores with overlapping excitation
and emission spectra provided that the ﬂuorophores are within suﬃcient proximity of each other
and typically takes place on the 1-10 nm distance regime [42]. FRET typically results in dimin-
ished donor emission intensity, reduced excited state lifetime and sensitised acceptor emission.
Nonetheless, energy transfer does not require the obligatory use of an inherrently ﬂuorescent
acceptor as other non-ﬂuorescent quenching agents can also be used [43]. The strong distance
dependence on the eﬃciency of the FRET process, following a 6th power dependence on D-A sep-
aration r, is commonly used tool to measure distances between ﬂuorophores and can be applied
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to address a wide range of questions in structural biology, macromolecule interaction analysis
and biological imaging from the ensemble down to single molecule level [44]. Furthermore, this
strong distance dependence also allows the FRET to have great potential for homogeneous sens-
ing assays and diagnostics as FRET acceptors free in solution do not contribute to the measured
signal [45]. The distance dependence on the rate of energy transfer, kT , from a donor to an
acceptor is given by:
kT (r) =
1
τD
(
R0
r
)6
(1.1)
Where τDis the lifetime of the donor in the absence of acceptor, R0 is the distance at which
50 % FRET eﬃciency occurs and r is the interﬂuorophore distance separation. R0 takes a
characteristic value for a given pair of ﬂuorophores and can be calculated using:
R0 =
9000(ln10)κ2QD
128pi5Nn4
∞ˆ
0
FD(λ)εA(λ)λ4dλ (1.2)
where QD is the quantum yield of the donor, N is Avogadro's constant, n is the refractive index
of the medium and κ2 describes the relative orientation of the donor and acceptor transition
dipoles. The integral term describes the degree of overlap between the donor ﬂuorescence and
acceptor absorption with respect to wavelength. The overall FRET eﬃciency, E, (i.e. the ratio
of photons emitted by the acceptor to those absorbed by the donor) is given by:
E =
kT (r)
τ−1D + kT (r)
=
R60
R60 + r6
(1.3)
Experimentally, FRET eﬃciency can be calculated by measuring the steady-state ﬂuorescence
intensity or excited state lifetime of the donor in the presence and absence of acceptor :
E = 1− FDA
FD
(1.4)
E = 1− τDA
τD
(1.5)
Various combinations of ﬂuorescent organic dyes, proteins, lanthanide complexes, polymers
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and metallic nanoparticles have been utilised in FRET-based biosensing[46] [47] [48][49][50].
Traditional FRET sensing suﬀers from several important drawbacks; for instance sensitivity of
some ﬂuorophores to photobleaching under sustained excitation, susceptibility to interference
from background autoﬂuorescence, inadvertant direct excitation of acceptor ﬂuorophores at the
donor excitation wavelength causing signal contamination and limited interﬂuorophore Förster
distances resulting in limited energy - thus FRET is not necessarily suitable tool to measure
interactions between high molecular weight biological macromolecules. [44][25].
1.2.4 Quantum dots as FRET donors
Quantum dots possess several properties that allow them to serve as particularly attractive
alternatives to organic dye and protein ﬂuorophores in FRET-based sensing. For example, the
colloidal nature of QDs leads to them having a large eﬀective surface area and provides the ability
to array multiple FRET acceptor molecules around a single QD donor. In addition, as FRET
eﬃciency is largely governed by the spectral overlap of the donor emission and acceptor excitation
spectra, the QD emission can, in theory, be tailored to be complementary to any acceptor of
choice by tuning the size and composition of the nanocrystal. Experiments using convential
organic FRET pairs are also complicated by the potential for non-FRET based acceptor emission
due to direct excitation at the donor wavelength and often require deconvolution of composite
emission spectra. This is largely a reﬂection of the combination of the small Stokes shift and
broad excitation spectra of many organic dyes [51]. The ability to excite QDs at essentially
any wavelength below the absorption onset provides a convenient means to avoid such direct
excitation simply by choosing excitation windows that correspond to acceptor absorption minima
[41].
An important and potentially complex consideration is whether the QD-dye FRET process
is commensurate with that associated with conventional dye-dye pairs and obeys Förster formal-
ism. It is possible to systematically study the eﬀect of QD-dye distance dependence of FRET
by using peptides containing a (YEHK)n peptide repeat motif. This motif behaves like a rigid
rod-like spacer of length depending on the value of n. Stoichiometric conjugates of QDs and
dye-labeled (YEHK)n peptides of diﬀerent length exhibit an r6 dependence of E, consistent
with classical FRET formalism [52]. In the case of the use of Au nanoclusters as FRET accep-
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tors which quench ﬂuorescent dye and QD emission, systematic variation of QD-Au separation
reveals an r4 dependence on E, allowing energy transfer to occur over distances beyond those
expected for a typical Förster-like mechanism [52]. In addition, modeling electronic couplings
between QDs and other organic ﬂuorophores based on time-dependent density functional theory
provides results consistent with dipole approximation of FRET [53]. Finally, E is dependent on
the relative orientations of the transition dipoles of the acceptor and donor with respect to each
other. This is given by the orientation factor, κ2 (equation 1.2). Provided that the donor and
acceptor orientations randomise by rotational diﬀusion prior to energy transfer, κ2 is assumed
to be 2/3. Room temperature polarisation microscopy has shown the transition dipoles of CdSe
QDs to be 2D degenerate, suggesting a degree of dipole randomisation [54]. In addition, given
the relatively large size of QDs and the inability to control the precise orientation of of acceptors
on the surface allows the relative orientations of QD donor and dye acceptor to be on average
random, thus in an ensemble of QD-dye acceptors, κ2 can be assumed to be 2/3 [55].
1.2.5 Quantum dots in FRET biosensing
DNA sequencing, detection of hybridisation of complementary oligonucleotides and enzymatic
processing can be routinely analysed using a multitude of ﬂuorometric approaches based on
energy transfer [56]. QDs have been tailored to detect speciﬁc DNA sequences by means of
energy transfer to proximal gold nanoparticle or dye quencher groups. For example, homoge-
neous binding assays have been developed where a target DNA sequence cross-links two distinct
oligonuleotides - one labeled with a ﬂuorescent dye and the other with a terminal biotin - by
sequence-speciﬁc base pairing (Figure 1.4, D) The biotin group can further bind to streptavidin-
coated QDs to form a complex with an associated FRET signature depending on the overall
dye:QD ratio. This signature can be characterised by ensemble time-resolved ﬂuorescence or de-
tection of dye/QD coincident photon bursts in single diﬀusing QD-DNA assemblies by confocal
microscopy [6]. Numerous systems analagous to molecular beacons have also been developed,
whereby target DNA sequence hybridisation increases the distance at which a monovalent gold
cluster/dye quenching agent, tethered to the QD by a ssDNA linker, is separated from the QD
surface resulting in enhanced QD emission [57]. Hybridisation events with chromosomal DNA
can also be imaged in ﬁxed cells using DNA-modiﬁed hydroxy terminated QDs in a procedure
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analagous to ﬂuorescence in situ hybrisation (FISH), with such QD probes showing low lev-
els of non-speciﬁc binding. Finally, elaborate DNA transformations such as telomerisation and
replication can also be detected via QD energy transfer by virtue of enzymatically-incorporated
ﬂuorescent deoxynucleotide triphosphates analogues [58]. Here, QDs modiﬁed with a ssDNA
oligonucleotide primer serve as a template substrate for telomerase - in short, a critical ribonu-
cleoprotein complex that prevents the abberant loss of genetic information accumulated over
many cycles of cell-division and DNA replication. Texas-red labeled dUTPs are enzymatically
added to the terminus of the ssDNA template, resulting in QD-dye energy transfer and allowing
the observation of telomerase dynamics.
Nucleic acids can also be engineered by systematic in vitro evolution approaches to selectively
recognise targets other than complementrary nucleotide sequences, such as peptides, proteins
and other small molecules [59]. Aptamers representative cost-eﬀective alternative to antibody-
based sensing as they are amenable to chemical synthesis and chemical modiﬁcation and are
stable under a broad range of conditions [60]. The QD photoluminescence quenching properties
exhibited by gold nanoparticles have been used in a multiplexed sensing assay for the parallel
detection of cocaine and adenosine. Here, gold nanoparticles and diﬀerent QDs with distinct
emission maxima are cross-linked by means of ssDNA aptamers with speciﬁcity for either adeno-
sine or cocaine [49, 61]. The AuNP-mediated cross-linking allows a dual mechanism of analyte
detection based on both QD-speciﬁc photoluminescence and colourimetric readout indicative of
the dispersion-state of AuNPs due to interparticle-plasmon coupling. The cross-linked nanopar-
ticle assemblies exhibit quenched photoluminescence owing to the the AuNP-QD proximity,
however, addition of down to c.a. 120 µM concentrations of the adenosine/cocaine targets re-
sults in a structural switch in the respective aptamers, leading to nanoparticle dispersion and
recovery of photoluminescence.
Distinct from nucleic-acid based systems, several assays have been developed which can
measure the activity of hydrolytic enzymes, speciﬁcally proteolytic activity (Figure 1.4, A). Nu-
merous assay conﬁgurations have been reported, which diﬀer slightly in details of bioconjugation
methods, but in essence employ a QD conjugated to a number of FRET acceptors via an in-
termediary protease-cleavable peptide substrate. In response to proteolytic activity, the FRET
acceptor is liberated from the vicinity of the QD, resulting in dequenching of QD photolumi-
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nescence [62][63][64]. Through judicious selection of QD-ﬂuorophore donor-acceptor pairs, it is
possible to realise homogeneous reactions where the activity of multiple protease enzymes can be
assayed simultanesouly (i.e. multiplexing) [3][65]. As opposed to using QDs as energy transfer
donors in protease sensing, they can also serve as eﬃcacious acceptors in bioluminescence en-
ergy transfer. For example, in a simple approach without need for elaborate derivitization of the
nanoparticle's surface, QDs can be conjugated to the bioluminescent protein luciferase through
an intermediary protease substrate [65]. Oxidation of the luciferase substrate coelenterazine
results in QD photoluminescence in the absence of external illumination due to energy transfer.
Proteolytic cleavage of the intermediary peptide, however, liberates the luciferase from the QD
surface and thus prevents energy transfer from taking place.
It is also possible to extend QD-FRET to the detection of unrelated bacterial enzymes such
as β−lactamases - an important family of enzymes involved in cell-wall processing which often
confer resistance to various antibiotics [4]. Here, a Cy5-labeled, biotinylated derivative of a
β−lactamase substrate quenches the emission of streptavidin-coated QDs. Energy transfer is
prevented upon enzymatic cleavage of the substrate and restores QD-speciﬁc photoluminescence
(Figure 1.4, B). Whilst the assay design is simple, the approach is somewhat limited by the need
to synthesise the substrate analogue and the fact that the structure of the substrate, namely the
intermediary linker between the hydrolyzable component and the biotin group of the substrate,
was shown to have a signiﬁcant inﬂuence on enzyme accessibility.
Other biocatalytic transformations can be detected using QD-speciﬁc electrical properties.
For example, enzyme-dependent tyrosine oxidation can be detected using peptide-conjugated
CdSe/ZnS QDs. Tyrosinase-generated quinone derivatives of tyrosine result in quenching of QD
photoluminescence due to electron transfer which can be subsequently recovered upon proteolytic
cleavage of the peptide[66] [67].
1.2.6 Limitations of QD-FRET
Despite the numerous beneﬁts of the use of QDs in FRET-based biosensing as evidenced by the
diverse range of their applications which have been realised in a relatively short space of time,
they are still limited by several important caveats. For example, commercially available water
soluble QDs are normally derivitized with proprietary amphiphilic polymer or phospholipid
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D
QD Energy transfer  biological detection systems
Figure 1.4: Examples of quantum dot-based FRET biosensing assays ([3][4][5][6]). A) Protease
detection ; B) β-lactamase detection using a biotinylated ﬂuorescent substrate analogue; C)
Small-molecule detection (maltose) based on displacement of a quencher analogue; D) Detection
of DNA hybridisation through formation of a DNA-QD nanoassembly.
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coatings which contribute to the overall hydrodynamic radius, hence the distance of closest
approach of the D-A pair will be limited and also the maximum attainable FRET eﬃciency. In
addition, an additional layer of streptavidin to the QD surface for further derivitization with
biotinylated molecules further contributes to the overall D-A separation and it may be diﬃcult
to ascertain the total number of available biotin binding sites per QD. Single molecule imaging
and time-resolved FRET studies are limited by the inherrent intermittent nature of core/shell
structure QD emission (i.e. blinking). Methods to eventually circumvent this issue may include
the use of QDs of more elaborate graded shell composition, such as CdZnSe/ZnSe, which exhibit
continuous non-blinking emission [68]. The utility of QDs as eﬀective FRET acceptors has been
considered to be limited owing to their long exciton lifetime and broad excitation. Nonetheless,
under certain circumstances, QDs can serve as energy acceptors, particularly in the case of the
use of lanthanide-based donors which exhibit long luminescence lifetimes on the ms timescale.
Such systems exhibit exceptionally large Förster radii providing new opportunities for long-range
FRET biosensing [69]. Finally, robust and reproducible methods of preparing and purifying
stable QD-biomolecule conjugates of well-deﬁned structure and stoichiometry remain as ongoing
technical challenges [70].
1.3 Gold nanoparticles
1.3.1 Synthesis, surface chemistry and biological modiﬁcation
The optical properties of gold nanoparticles (AuNPs) have been used fortuitously as glass-
staining additives since ancient times [71]. Monolayer protected AuNPs are now routinely
prepared by a broad variety of colloidal routes in both organic and aqueous solvents, providing
the ability to readily functionalise with both hydrophobic and hydrophilic surface ligands, but
generally involve reduction of gold salt precursors in the presence of additional stabilising agents
to resist particle aggregation. Thiols, amines, phosphines and a range of polymers or dendrimers
can serve as appropriate stabilisers and are often amenable to further chemical derivitization
[71]. Due to solvent compatibility, biological applications often employ water-soluble AuNPs
prepared by the reduction of HAuCl4 by sodium citrate or reduction of preformed gold nuclei
'seeds' [72]. This route provides approximately spherical particles on the 10 - 100 nm size regime
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with reasonably narrow size distributions. Surface-bound citrate molecules provide electrostatic
stabilisation of the colloid, however, the labile nature of the Au-citrate interaction often neces-
sitates replacement with higher-aﬃnity stabilising ligands to aﬀord greater resilience towards
particle ﬂocculation. This can be achieved through ligand-exchange reactions with hydrophilic
thiols (e.g. thioalkyl oligoethylene glycols) and phosphines to render the particles less sensitive
to electrolyte-induced aggregation and non-speciﬁc protein binding [73][74]. Various analytical
techniques have been utilised to investigate the rich chemistry of interfacial ligand exchange
reactions, including NMR, electron spin paramagnetic resonance (EPR), surface enhanced Ra-
man scattering (SERS) and ﬂuorescence quenching, providing insight into the structural and
mechanistic details of the process with occasionally conﬂicting models. Overall, interfacial lig-
and exchange has been shown to be dependent on the structures of the incoming and displaced
ligands and the size of the nanoparticle [75][76][77][78]. Nonetheless, ligand exchange approaches
have provided a convenient method to functionalise AuNPs with numerous biomolecules such
as DNA, peptides and proteins owing to the ease of incorporation of thiols into these molecules
though well-established synthetic procedures and site-directed mutagenesis [79][80] [81]. In ad-
dition to thiol/Au-driven self-assembly of AuNP-biomolecule composites, site-selective ligation
reactions, such as the azide/alkyne cycloadditions can provide an alternative means of bioconju-
gate formation and facilitates selective biomolecule orientation on the nanoparticle surface and
assists in preserving protein function relative to less selective covalent coupling methods (e.g.
carbodiimide coupling) [82, 83].
Biofunctional gold nanoparticles have been proposed to serve as useful reagents in nanomedicine
and have been demonstrated to serve as contrast agents for cellular imaging, drug delivery plat-
forms, gene transfection devices and tools for targeted thermal ablation of tumors [84]. One
of the most useful properties of gold nanoparticles is their intense and environment-sensitive
optical absorption which allows them to provide the basis of operation for a wide range of novel
biological detection probes.
1.3.2 Localised surface plasmon resonance
Well-dispersed noble metal nanoparticles, such as silver and gold, exhibit intense optical extinc-
tion spectra owing to localised surface plasmon resonance (LSPR). In contrast to semiconductor
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nanocrystals where quantum conﬁnement eﬀects govern the optical absorption and photolumi-
nescence emission characteristics, the LSPR exhibited by gold nanoparticles (> c.a. 3 nm in
diameter) can largely be described using a classical picture of electrons. LSPR arises due to
coherent, collective dipolar oscillations of conduction band electrons in response to excitation
with visible light (Figure 1.5) and results in an intense absorption band, known as the surface
plasmon absorption band (Figure 1.6, A). All metals posess this characteristic, however noble
metals (Au, Ag) and copper have particular practical utility due to their resistance to oxide for-
mation and chemical stability and the fact their LSPR absorption predominantly occurs in the
visible region of the electromagentic spectrum [7]. The basis of the surface plasmon resonance
band and the associated intense absorption properties of colloidal gold was ﬁrst rationalised by
Mie's solutions to Maxwell's equations for spherical particles of radius, R, signiﬁcantly smaller
than the wavelength of incident light (R λ) and provides a relationship between the extinction
cross-section, σex (i.e. absorption + scattering) as a summation over all electric and magnetic
oscillations, given by;
σex =
24pi2R3ε2/3m
λ
ε2
[ε1 + 2εm]2 + ε22
Where λ is the wavelength of light εm is the dielectric constant of the surrouning medium
and ε1 and ε2 are the real and imaginary components of the dielectric constant of the metal
(ε = ε1 + iε2) [85]. The position, intensity and shape of the plasmon absorption band is de-
pendent on a number of factors, such as nanoparticle composition, morphology (e.g. nanorods),
anisotropy, size and size distribution due to size-dependent dielectric properties of the metal (
intrinsic size eﬀects). In the case of larger particles, higher-order multipolar oscillations of the
conduction band electrons are also possible which can inﬂuence the plasmon band position and
width (extrinsic size eﬀects) [86, 8][71]. Furthermore, the modiﬁcation of the nanoparticle local
dielectric environment and refractive index due to solvent and/or surface ligand coating can
also inﬂuence the plasmon absorption [86]. Interparticle proximity is another important factor
which can profoundly modify the surface plasmon behaviour due to the interparticle plasmon
coupling. This phenomena, associated with nanoparticle aggregates is manifested as a marked
red-shift and broadening of the plasmon absorption band and typically accompanied with a
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Figure 1.5: Plasmon oscillation of a metal nanosphere in response to an incident electric ﬁeld
[7]
red to purple/blue colour change of the particle solution, with the overall aggregate size and
interparticle spacing inﬂuencing the optical properties (Figure 1.6 B) [87].
1.3.3 Colourimetric LSPR biosensing
The ability to synthesise gold nanoparticles in aqueous solvent, their rich surface chemistry
and amenability to bioconjugation has enabled the use of their aggregation-dependent optical
properties in numerous colourimetric biosensing systems to detect small molecules, proteins and
biocatalytic transformations [88]. A paradigm example of gold nanoparticle-based biosensing is
represented by the DNA-hybridisation assays of Mirkin, where thiol-DNA modiﬁed AuNPs are
cross-linked by means of a complementary ssDNA target sequence [89]. This principle has since
been extended to detect the activity of a range of DNA processing enzymes, such as sequence-
speciﬁc endonucleases, ligases and methyltransferases, which can augment the structure of DNA-
crosslinked nanopartiple assemblies [90][91] [92]. Other elaborate colourimetric sensing systems
based on DNA-conjugated AuNPs have been devised which exploit conformational changes
induced upon binding of DNA aptamers to diverse target molecules, such as heavy metal cations,
alkaloids, proteins and cancerous cells (Figure 1.7, E) [49] [60][93][94]. Heterostructured gold
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Figure 1.6: (A) Normalised optical absorbance of gold nanoparticles, as determines by UV-Vis
spectroscopy, of diﬀerent dimensions [8] and (B) aggregation-dependent plasmon band broad-
ening [9]
nanostructures, such as gold SiO2/Au nanoshells, provide an alternative means to tune the
plasmon absorption band to wavelengths signiﬁcantly longer than those exhibited by typical
solid-gold nanoparticles to the NIR and beyond [95]. This allows the realisation of colourimetric
immunoassays based on aggregation-dependent plasmon red-shifting which operate in spectral
windows where biological matrices, such as plasma and blood, are particularly transmissive.
For example, antibody-coated nanoshells can be induced to form higher-order aggregates upon
binding to a multivalent target antigen, resulting in a shift in absorption spectrum which can
be used to detect sub-nanogram quantities of target analyte in <10 min (Figure 1.7, B) [10].
In addition to the novel properties of DNA-based hybrid nanostructures, the robust optical
properties of gold nanoparticles allow them to serve as persuasive alternatives to ﬂuorogenic
or radioisotope labeled substrates in enzyme activity assays, owing to their insensitivity to
photobleaching and relative safety. For example, a number of protease detection strategies have
been reported which rely of proteolytic degradation of substrate peptides which can aﬀect the
aggregation of gold nanoparticles. For example, a protease substrate, containing two cysteine
residues positioned to ﬂank the hydrolysis site, can cross-link citrate-stabilised AuNPs through
the divalent thiol-Au interaction, leading to particle aggregation and an associated red-shift and
broadening in plasmon absorption. Proteolytic cleavage, however, separates the two cysteine
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residues and prevents particle agglomeration [96]. A real-time protease assay has also been
developed based on pi-pi stacking driven association of peptide-modiﬁed AuNPs by means of
appending Fmoc groups, with proteolytic cleavage of the peptides resulting in dispersion of the
nanoparticles upon loss of the Fmoc interaction (Figure 1.7, A) [9].
Several colourimetric AuNP sensing appoaches have been implemented to detect enzyme-
mediated phosphorylation by protein kinases (see following section). For instance, the substan-
tial changes in peptide charge upon phosphorylation can be exploited to either cause agglom-
eration or dispersion of AuNPs upon adsorption to the nanoparticle surface. For instance, a
non-phosphorylated substrate peptide with cationic character can elicit aggregation of anionic
AuNPs due to charge screening, whereas the anionic phosphorylated equivalent lacks this ca-
pability (Figure 1.7, C) [11, 97]. It is of note that this principle can be readily extended to
detect the antaganostic enzyme modiﬁcation of phosphatase catalyzed dephosphorylation [98].
Whilst these approaches are simple, and do not require sophisticated nanoparticle derivitisation
procedures, the fact that the AuNPs in such assays are stabilised with a labile citrate coat-
ing renders them susceptible to electrolyte-induced ﬂocculation and/or non-speciﬁc binding to
biomolecules [99]. An alternative approach to electostatic interaction-based detection of kinase
activity is the use of high aﬃnity biospeciﬁc interactions. For instance, using a γ-biotin deriva-
tive of ATP, AuNPs coated with kinase substrate peptides can be enzymatically biotinylated and
subsequently bind to streptavidin-coated AuNPs, providing a convenient colourimetric response
which can be applied to screen potential kinase inhibitors (Figure 1.7, D) [13].
colourimetric biosensing assays using AuNPs in common with all assays, are subject to sev-
eral limitations. For instance, gold-based biosensing often requires substantial engineering of
the nanoparticle surface, possibly leading to precarious colloidal stability in biological matrices
thereby limiting reagent shelf-life [100, 80]. In addition, the propensity of AuNPs to undergo
complex ligand exchange reactions with thiols and other biological molecules (e.g. DTT, re-
duced glutathione) may cause premature dissociation of biodetection motifs immobilised on the
nanoparticle surface [84] . Finally, the need for scalable, robust synthesis methods and char-
acterisation techniques of biologically-modiﬁed gold nanoparticles presents a current bottleneck
to the realisation of their widespread application in biology [101].
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Figure 1.7: Representative examples of colourimetric gold nanoparticle biosensing. A) pro-
teolytic dispersion of aggregated nanoparticles; B) Antigen-mediated immunoaggregation; C)
Electrostatic aggregation of anionic nanoparticles by cationic peptides. Alternatively, the in-
creased negative charge of the peptide upon phosphorylation prevents aggregation; D) Kinase
catalysed biotinylation of peptide-modiﬁed gold nanoparticles. Exposure to streptavidin-coated
gold nanoparticles leads to interparticle crosslinking and plasmon broadening; E) Aptazyme-
based detection of heavy-metal cations. The presence of the target cation results in self-cleavage
of the aptamazyme, preventing the cross-linking of nanoparticles derivitised with complementary
oligonucleotides [9][10][11][12][13].
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1.4 Protein kinases
1.4.1 Background
The cell's ability to modify amino side chains through enzymatic post translation modiﬁcation
serves to greatly enhance the diversity of proteins by introducing new chemical functionalities,
distinct from the those of the standard repertoire of proteogenic amino acids, and provides new
potential layers of regulation [102]. Amongst the wide range of post-translational modiﬁcations
which exist, protein kinase mediated reversible phosphorylation of serine/threonine/tyrosine
residues is one of the most widely employed regulatory device found in eukaryotic cells (Figure
1.8). The protein kinases are one of the largest families of proteins encoded by the human
genome with more than 500 identiﬁed to date [21]. Protein phosphorylation plays a pivotal
role in the integration of extracellular signals with intracellular activities and is responsible
for the regulation of fundamental cellular processes, including stem-cell diﬀerentiation, embryo-
genesis, cell-cycle control and gene expression [103]. In consideration of the central role that
these enzymes play in cell biology, the dysfunction or deregulation of protein kinase activity
is often manifested in the development of numerous disease states including chronic inﬂamma-
tion, neurodegeneration, osteogenic disorders, cardiovascular disease and cancer [104]. This is
a reﬂection of the fact that each of the classically deﬁned `hallmarks of cancer' (i.e. evasion of
apoptosis, unlimited replicative potential, self-suﬃciency from growth factors, insensitivity to
anti-proliferative cues, sustained angiogenesis, cell invasion and metastasis) is intimately linked
to the aberrant action or inaction of protein kinases in the cell's regulatory circuitry [105].
In light of the central role that these enzymes play in the development of numerous diseases,
protein kinases are considered to be attractive targets for pharmaceutical intervention and second
only to G-protein coupled receptors in terms of signiﬁcance as a drug targets [106]. As such,
there is a strong impetus to develop assays and high-throughput screening procedures to provide
quantitative information on kinase activity for drug discovery and a myriad of biochemical in
vivo and in vitro assay technologies are in use. A host of diverse solid-phase and solution-based
protein kinase assays have been developed. Thus it is necessary to provide a brief discussion of
current screening approaches available and their advantages and limitations, paying particular
attention to state-of-the-art techniques currently used in industrial drug discovery programmes.
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Figure 1.8: ATP-dependent protein kinase phosphorylation
1.4.2 Fluorescence polarization anisotropy and time-resolved energy
transfer
Radioisotope-based methods to measure kinase activity typically employ radiolabeled γ−32P-
ATP as a cosubstrate, with the radiolabeled phosphate becoming incorporated into the kinase's
peptide/protein substrate followed by separation of the labeled reaction product and detection
by scintillation counting or autoradiography. This method is simple, sensitive, rapid and generic,
however the use of expensive and potentially hazardous isotope tracers and the non-homogeneous
format (i.e. necessity for product separation from excess γ−32P-ATP) prevents this approach
from being broadly applicable to high-througput screening [107][108]. Fluorescence-based detec-
tion techniques have therefore superceded radioisotope labeling owing to the combined beneﬁts
of sensitivity and amenability to miniaturisation and automated high-throughput screening.
Two of the most widely used methods to screen kinase activity are ﬂuorescence polarization
anisotropy (FP) and time resolved FRET (HTRF), owing to their homogeneous nature (i.e.
no washing steps) and simplicity in operation. Fluorescence polarization makes use of the
diﬀerences in rotational diﬀusion between macromolecules of diﬀerent sizes [109]. For instance,
a peptide will rotate in solution much more rapidly than a typical antibody. For example, as
applied to kinase activity, a ﬂuorescently labelled substrate peptide is free to rotate relatively
rapidly in solution. Upon enzymatic phosphorylation of the peptide and subsequent binding
of a phospho-speciﬁc antibody or chelating nanoparticle, the rotational diﬀusion of the peptide
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is substantially modiﬁed owing to the increased eﬀective mass of the complex. The signal
is generated upon illumination with vertically polarised light and detecting the emitted light
intensity parallel (I‖) and perpendicular (I⊥) to the plane of excitation. This generates a
dimensionless anisotropy ratio r [42]:
r =
I‖ − I⊥
I‖ + 2I⊥
The ratiometric nature of the FP signal allows the measurement to be less prone to well-to-well
variations due to the presence of coloured samples and is independent of the total ﬂuorophore
concentration, however the approach is sensitive to interference due to scattering and autoﬂuo-
rescence, although these eﬀects can be reduced through the use of ﬂuorophores with red-shifted
emission proﬁles [20]. Furthermore, FP requires the use of antibodies and is restricted to low
molecular weight peptide substrates. Finally, the FP assay is a loss-of-signal format which is in-
herently limited by the fact that a relatively high enzyme turnover is required prior to producing
a statistically signiﬁcant signal above the background [107].
Homogeneous time-resolved FRET (HTRF) is one of the most powerful techniques available
to biomolecular screening owing to its greatly diminished sensitivity to background autoﬂuores-
cence. HTRF makes use of the unique luminescent properties of certain rare lanthanides such
as europium (Eu3+) and terbium (Tb3+) [14]. These metals exhibit exceptionally long lumines-
cence decay times on the order of milliseconds when encapsulated within a suitable chelating
group. The chelate serves to relay excitation energy to the lanthanide due to very low absorp-
tion coeﬃcients of the lanthanides in isolation, enhance the quantum yield of the lanthanide
and provide functional groups for bioconjugation [110]. Typically, an anti-phosphoaminoacid
antibody is conjugated to the lanthanide chelate (cryptate) which can bind to a biotinylated
phosphopeptide. The biotin, in turn, serves to bind to a streptavidin-conjugate of the ﬂuo-
rescent protein allophycocyanin (APC), known as SAXL. Assembly of the complex results in
energy transfer from the cryptate to APC. By exciting the cryptate with a brief pulse of illumi-
nation and detecting cryptate and APC ﬂuorescence following a time-delay, residual background
autoﬂuorescence can be eﬀectively eliminated from the measured signal owing to its tendency
to decay on the order of nanoseconds (Figure 1.9) [14].
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Figure 1.9: Principle of time-gated HTRF measurement [14]. The sample is brieﬂy illuminated
with an excitation pulse at 337 nm, followed by a time delay to allow for the decay of autoﬂu-
orescence originating from biological matrices and test compounds etc. Energy transfer in the
Eu-cryptate and SAXL complex is subsequently detected by measuring the emission intensities
at 665 nm and 620 nm.
HTRF represents one of the most versatile and robust assay technologies available. The
assay is somewhat limited by the need for costly cryptate-labeled phospho-speciﬁc antibodies
and preparation of high-molecular weight APC conjugates.
1.4.3 Fluorescent synthetic peptides and genetically-encoded ﬂuores-
cent reporters
FRET assays for kinases can also be used in antibody-free context, using substrate peptides la-
beled with both a FRET donor and acceptor. Phosphorylation of the peptide alters its sensitivity
to proteolytic cleavage which results in the separation of the donor and acceptor and changes
in FRET eﬃciency [111]. This is a convenient assay amenable to miniaturisation but requires
care in substrate design due to limited FRET for higher molecular weight peptides and may
be susceptible to oﬀ-target eﬀects in the search for kinase inhibitors due to the coupled-enzyme
detection format. To circumvent the limitations imposed by the sensitive distance-dependence
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Technology Assay principle Advantages Limitations
FRET Diﬀerential protease sensitivity of D-A dye-labeled protein
kinase substrate peptide
Homogeneous, high-throughput,
antibody-free
Diﬃcult substrate design,
coupled enzyme assay
HTRF Energy-transfer between Eu3+/Tb2+labeled phosphospeciﬁc
antibody and dye-labeled substrate
peptide/allophycocyanin-conjugated streptavidin
Low background signal Antibody dependent, limited
choice of D/A pairs, stability of
chelate
AlphaScreen Photogenerated singlet oxygen proximity-dependent
luminescence. Photosensitiser-labeled donor and singlet
oxygen-sensitive chemoluminescent beads bind to each other in
response to phosphorylation of a substrate peptide. The
increased proximity results in diﬀusion of the singlet oxygen to
the acceptor beads and enhanced luminescence.
Low enzyme consumption, Sensitive to ambient light, assay
data points can only be read
once, sensitive to compound
interference
Fluorescence polarization Diﬀerent rotational diﬀusion and rates of ﬂuorescence
depolarisation of polarised light originating from
ﬂuorophore-labeled peptides.
Miniaturisation potential, low
enzyme consumption, bead-free
Limited size of peptide,
antibody-dependent, sensitive to
scattering, loss-of-signal format
ATP depletion ATP consumption in the kinase assay is detected using luciferase
activity as a reporter of remaining coenzyme
Non-radioactive, antibody-free Inadvertent luciferase inhibition,
loss-of-signal format,
Fluorescence quenching Binding of phosphorylated dye-labeled peptide to
phosphate-binding Ga3+-modiﬁed nanoparticles quenches
ﬂuorescence
Antibody-free Loss-of-signal format
Scintillation proximity assay Capture of 33P- labeled biotin-phosphopeptide by
streptavidin-coated scintillant beads
Low cost, ﬂexibility in
substrate, homogeneous reaction
Safety, limited ATP
concentration range, poor
signal:background
Time-resolved immunoassay Capture of biotinylated phosphopeptide on streptavidin-coated
well plates followed by binding of lanthanide-labeled antibody
and luminescence detection
Low background Antibody-dependent,
non-homogeneous
Table 1.1: Comparison of currently available protein kinase assay technologies
of FRET, ﬂuorescently labeled peptides can be employed in which the intrinsic ﬂuorescence in-
tensity is modiﬁed upon phosphorylation. For example, the ﬂuorescent dye rhodamine 110 has
suppressed ﬂuorescence when two primary amino groups in its structure are covalently linked,
for instance to two peptide sequences, to form a bisamide. If these peptides are phosphorylated,
they are protected against proteolytic degradation but can be cleaved from the dye in their non-
phosphorylated state by a suitable aminopeptidase leading to substantial dequenching of the
dye [112]. Other sophisticated designs have employed a synthetic substrate peptide containing
an artiﬁcal amino acid which exhibits Mg2+-dependent chelation-enhanced ﬂuorescence upon
phosphorylation [113].
FRET-based intracellular reporters of real-time kinase activity have been developed which
have the notable advantage of being able to conduct assays in a highly physiologically relevant
environment [114]. These modular protein reporters consist of two distinct variants of green
ﬂuorescent protein (GFP) separated by an intervening kinase substrate domain and a phospho-
rylation recognition (SH2) domain. Provided that the GFP variants, speciﬁcally CFP and YFP,
are within a suﬃciently close distance, they can participate in energy transfer. Phosphoryation
of the tyrosine within the substrate domain results in binding to the SH2 domain, bringing the
GFP variants into close proximity for increased FRET.
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1.4.4 Nanoparticle-enabled approaches to detect protein kinase activ-
ity
Whilst AuNPs have been tailored to detect kinase activity through enzyme-dependent agglu-
tination/dispersion of the nanoparticles, several other nanoscale-speciﬁc phenomena have been
applied to kinase detection. For example, two populations of magnetic nanoparticles, coated with
a kinase substrate and complementary phosphopeptide-binding SH2 domains, can selectively co-
alesce in the presence of kinase activity and disperse in the presence phosphatase activity, as
indicated by changes in NMR T2 relaxation rates [115]. This non-optical approach is especially
suited to strongly coloured or turbid samples such as cell lysates, but is somewhat limited the
need for complex instrumentation and sophisticated engineering of heterogeneous populations
of nanoparticles. Phosphopeptide detection has also been demonstrated using surface enhanced
Raman spectroscopy (SERS) using the electric ﬁeld-enhancing properties of gold and silver
nanoparticles [116], providing a means for label-free detection. Whilst quantum dot photolu-
minescence has not been applied to detect kinase activity per se, a FRET-based competitive
binding assay to identify molecules which bind to the conserved kinase ATP-binding site has been
developed. Here a recombinantly expressed kinase construct bearing a QD-aﬃnity peptide motif
was self-assembled on the surface of the nanocrystal. A boron-dipyrromethene (BODIPY)-ATP
analogue was designed to bind to the kinase-QD assembly through the enzyme's ATP binding
site, resulting in FRET from the QD to the BODIPY-ATP energy acceptor. Introduction of
ATP-binding site competitors was envisioned to displace the BODIPY-ATP molecule from the
QD assembly and result in diminished FRET. Control experiments, however, revealed that the
system was susceptible to direct binding of the BODIPY-ATP molecule to the QD surface, thus
signiﬁcantly limiting the utility of the assay [117].
Distinct from their optical properties, the inherent curvature of nanoparticle materials can
be utilised to create enhanced kinase assays to overcome limitations of other solid-phase enzyme
assays. For example, kinase assays can be conducted using peptide substrates immobilised
on a planar surfaces in chip format to allow large-scale parallel evaluation of diﬀerent peptide
sequences for biological activity [118] [119]. Some reports have suggested that a monolayer
of gold nanoparticles coated with kinase substrates can serve as an eﬃcacious alternative to
substrates on ﬂat surfaces, arguing that the curved nature of the particle allows a high peptide
42
loading density and aﬀords enhanced steric accessibility for the enzyme.
1.4.5 Summary
The ability to quantitatively measure the activity of enzymes which mediate post translational
modiﬁcations is of fundamental importance to drug discovery and to aid in our understanding
of basic enzyme function. A host of ﬂuorescence-based approaches have been developed to
measure enzyme activity based on the use of organic dyes and ﬂuorescent proteins. It is now
becoming increasingly apparent that biofunctional nanomaterials can serve as powerful reagents
for colourimetric- and ﬂuorescence-based biological detection due to their size-tuneable and
robust optical properties. Whilst they provide a persuasive route to avoid the use of radiolabeled
tracers and photobleaching-prone ﬂuorescent molecules, nanomaterial-based methods are not
without limitations and face several challenges which currently limits their pervasive application
in biosensing. For instance, reproducible methods of preparing large-scale quantities of puriﬁed
nanoparticle-biomolecule conjugates of well-deﬁned structure and stoichiometry are still in their
infancy relative to other small-molecule probes for biological labeling. In addition, there is
some ambiguity concerning the potential toxicity of nanomaterials which may arise due to their
inherrent physical dimensions or propensity to leach toxic consituent ions (e.g. Cd2+) [120].
1.5 Overview
The goal of this thesis is to develop novel enzyme assays based on the unique optical and
photoluminescent properties of semiconductor quantum dots and gold nanoparticles.
Chapter 2 seeks to develop an alternative method of protein kinase assay based on the
aggregation-dependent optical absorption properties of colloidal gold nanoparticles. Some pre-
viously reported gold-nanoparticle based kinase assays have been limited by the use of weakly
passivated nanoparticles prone to premature non-speciﬁc ﬂocculation and the need for multi-
step procedures or non-physiological surface-bound peptide substrates. In consideration of these
caveats, an alternative method is proposed which employs protein stabilised AuNPs in a homo-
geneous assay whereby a synthetic peptide substrate analogue in solution can elicit nanoparticle
aggregation in an enzyme-activity dependent manner.
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Whilst quantum dots have been applied in a diverse range of energy transfer (FRET) -
based biosensing systems, Chapters 3 and 4 seek to extend their use to the detection of protein
kinases - a family of enzymes hitherto unexplored using such an approach. Here, quantum
dots are rendered water soluble by means of ligand exchange with mercapo alkyl carboxylic
acids and further derivitised with peptide substrates for two model protein kinases. Kinase
catalysed phosphorylation of these QD-peptide conjugates is subsequently detected by means
of an acceptor dye-labelled phospho-speciﬁc antibody. The resultant close proximity of the
QD and acceptor dyes results in QD-dye energy transfer as revealed by steady-state and time-
resolved photoluminescence measurements. This simple and homogeneous assay can be applied
to measure inhibitor potency, suggesting that it may have utility in high-throughput drug-
discovery applications. Chapter 5 builds upon this work to demonstrate that this overall sensing
strategy has wider applications and can be readily generalised to detect functionally unrelated
enzymes distinct from protein kinases. This is illustrated by the demonstration that histone
acetyl transferases - a critical class of enzyme which regulates fundamental aspects of gene
expression - can be detected using an analagous approach using QD-based FRET. This suggests
that the enzyme assays developed here may have broad applicability and provides a generic
platform for the detection of arbitrary enzyme-catalysed post-translational modiﬁcations.
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Chapter 2
Kinase actuated
immuno-aggregation of gold
nanoparticles by bivalent peptide
substrates
2.1 Introduction
The ability to impart biological functionality to inorganic nanostructures has permitted the
development of a wide range of novel biological imaging and sensing probes. There are numerous
examples where aggregation-dependent interparticle plasmon coupling exhibited by colloidal
gold nanoparticles has been utilised to create convenient sensing platforms for biological analytes
such as nucleic acids, proteins and other small molecules. These sensing systems typically employ
gold nanoparticles which have been derivitised with speciﬁc recognition moieties such as DNA,
nucleic aptamers, avidin/biotin and antibodies. The presence of the analyte results in either
aggregation or dispersion of the nanoparticles and an accompanying change in the plasmon
absorption spectra. This principle has also been extended to the detection of the activity of
several enzymes such as proteases, protein kinases and other hydrolytic enzymes, owing to
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the numerous advantages associated with nanoparticle-based sensing, relative to traditionally
used isotopic and ﬂuorometric approaches. Many of these nanoparticle-based approaches employ
nanoparticle conjugates which serve as surrogate enzyme substrates and enzyme activity eliciting
a change in the nanoparticle dispersion. Whilst the robust photostability and high extinction
coeﬃcients of gold nanoparticles provide numerous advantages to these systems compared to
other techniques, this general approach has several important limitations. For instance, the
preparation of gold nanoparticle-substrate conjugates can be technically challenging, requiring
the use of cross-linking agents and additional puriﬁcation steps. Although self-assembly and the
strong gold-thiol interaction can be used to functionalise nanoparticles with substrate molecules
and peptides the nanoparticle surface energy will be invariably modiﬁed and possibly render
them susceptible to premature or irreversible ﬂocculation [80]. In addition, the precise surface
structure of the nanoparticle, local ion concentration and substrate packing density will also
serve as key determinants of enzyme accessibility and it is possible that steric constraints will
prevent the conjugate from acting as an accurate substrate mimic [121].
In light of these limitations, it was sought to design a gold-nanoparticle based enzyme sensing
system for protein kinase activity which was not dependent on the use of surface-immobilised
substrates. The system is based on the use of gold nanoparticles, functionalised with anti-
phospho amino acid antibodies, designed to coalesce by means of a bivalent peptide substrate
consisting of two tandem substrate sequences for a protein kinase separated by an oligoglycine
spacer (Figure 2.1). Enzymatic phosphorylation of the two covalently-linked substrate sequences
enables the peptide to cross-link the nanoparticles through immunorecognition by means of
complementary antibodies bound to the surface of the nanoparticles, resulting in a red-shift in
the particle absorption spectra due to interparticle plasmon coupling. It was envisioned that
this approach should provide several beneﬁts as the kinase substrate is free to diﬀuse in solution
and not conformationally restricted due to nanoparticle immobilisation. This method should
provide a more physiological mimic of natural substrates whilst endowing the assay with the
photophysical beneﬁts of gold nanoparticles and avoiding the use of radiolabels or ﬂuorogenic
tracers.
The tyrosine kinase Src was chosen as a model enzyme to develop the AuNP-based system
in conjunction with a synthetic peptide based on previously developed substrates, owing to
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Figure 2.1: Proposed approach for kinase-actuated immunoaggregation of antibody-modiﬁed
gold nanoparticles
previous kinetic and structural characterisation and implication in disease states [122] [108].
This peptide consisted of two copies of the enzyme substrate sequence linked by three glycine
residues (H2N-IYGEFKKK-GGG-IYGEFKKK-CONH2) to provide additional conformational
ﬂexibility and spacing in order to favour interparticle cross-linking.
Gold nanoparticles were derivitised with antiphosphotryosine antibodies by i) electrostatic
self-assembly or ii) thiol-directed immobilisation on the Au surface using a chemoselective cross-
linker.
2.2 Materials and Methods
2.2.1 Gold nanoparticles
40 nm citrate-stabilised gold nanoparticle colloids (9 x 1010 particles / mL) were purchased
from British Biocell International (Cardiﬀ, UK). Prior to further surface derivitization with
antibodies, the particles were concentrated by ultraﬁltration using a 10 KDa MWCO ﬁltration
device (4000 g) and resuspended in salt free 100 mM Na2PO4 (pH 7.5) to a ﬁnal concentration
of 1 nM.
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Figure 2.2: Experimental approaches employed to absorb antibodies on the surface of gold
nanoparticles; i) Electrostatic and ii) site-selective thiol-directed antibody immobilisation on
AuNP surface
2.2.2 Anti-phosphoamino acid antibody conjugation to gold nanopar-
ticles
2.2.2.1 Electrostatic assembly
Monoclonal antiphosphotyrosine (PT-66) was conjugated to 40 nm gold nanoparticles using an
electrostatic self-assembly procedure (Figure 2.2, i)) [123]. 200 µl of 40 nm AuNPs (1 nM)
in borate buﬀer (pH 9.0) were incubated for 1 hr with diﬀerent amounts of antibody to reach
diﬀerent ﬁnal concentrations of antibody (1 to 24 µg/ml) in order to determine the minimum
amount of antibody required to stabilise the sol against electrolyte-induced ﬂocculation. Follow-
ing incubation, NaCl was added to the AuNP/antibody solution to a ﬁnal concentration of 100
mM and the UV/Vis absorption spectra recorded to detect the presence of particle aggregation,
as indicated by a decrease in intensity at the sharp plasmon absorption band at ∼520 nm and
broadening in the spectra at wavelengths > 550 nm [96, 13].
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2.2.2.2 Antibody oxidation and cross-linker conjugation
All reactions, unless otherwise stated, were conucted in 1.5 mL polypropylene centrifuge tubes
(Eppendorf). Monoclonal anti-phosphoserine (clone PSR-45) and anti-phosphotyrosine (clone
PT-66) were obtained from Abcam (Cambridge, UK) and Sigma respectively. In order to pref-
erentially orientate antibodies on the colloids as to favour Fv region accessibility, a bifunctional
dithiol-hydrazide cross-linker was employed (Figure 2.3, A) [124] . This scheme involves selec-
tively modifying the antibody's Fc region by through the selective reaction between oxidised
carbohydrates and the hydrazide group of the cross-linker (Figure 2.3, B). Following which, the
high-aﬃnity multidentate gold-thiol interaction provides a means to preferentially orientate the
antibodies on the nanoparticle surface. The antibodies were ﬁrst buﬀer exchanged to 100 mM
Na2PO4 (pH 7.5) to remove the sodium azide preservative from the storage medium owing to its
propensity to react with aldehydes [125]. 10 µl of 100 mM sodium periodate (NaIO4) dissolved in
100 mM Na2PO4 (pH 7.5) was then added to a 100 µl (1 mg/ml) antibody solution and allowed
to react for 30 min at room temperature protected from light. The reaction was then quenched
with the adition of 500 µl of PBS. A 20 µl aliquot was then tested for the presence of aldehydes
by the addition of 60 µl 10 mg/ml Purpald® (4-Amino-3-hydrazino-5-mercapto-1,2,4-triazole,
Sigma) dissolved in 1 M aqueous sodium hydroxide. The presence of aldehydes was conﬁrmed by
the solution changing from colourless to deep purple in < 10 minutes. A 50 mM stock solution
of cross-linker (dithiolaromatic-PEG6-hydrazide, Sensopath Technologies, Bozeman, MT, USA)
was prepared in ethanol (>99.5%, Sigma) and stored at -200C prior to use. A 2 µl aliquot of
the linker stock solution was then added to the oxidised antibody solution and allowed to react
for 1 hr at room temperature. Following which, the antibody-linker conjugate was puriﬁed by
four rounds of 10-fold concentration and dilution in 40 mM HEPES (pH 8.0) using a 10 KDa
MWCO centrifugal ﬁltration device (Millipore).
2.2.2.3 Antibody conjugation to gold nanoparticles
20 µl of the antibody-linker solution was added to 200 µl of the 1 nM 40 nm AuNPs in 100 mM
Na2PO4 (pH 7.5), mixed gently by pipetting to ensure that the solution was homogeneous and
allowed to stand for 30 mins at room temperature to allow linker immobilisation on the gold
surface. Following which 100 µl of 10 µM PEG-thiol (CH3O-PEG-SH) (5000 g/mol, Shearwater
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Figure 2.3: Structure of cross-linker (A) and periodate oxidation of antibody carbohydrates
followed by hydrazone formation (B)
Polymers) in 40 mM HEPES (pH 8.0) was added to the solution to passivate any exposed
gold surfaces and allowed to stand for an additional 20 minutes. Alternatively, the PEG-thiol
addition was substituted for 20 µl of 1% (w/v) BSA in 40 mM HEPES (pH 8.0). The resultant
conjugates were puriﬁed by centrifugation (2000g, 10 minutes) and resuspension of the particle
slurry in 0.1% (w/v) BSA in PBS three times and stored at 40C before use.
2.2.3 Nitrocellulose blotting and silver enhancement assay
Nitrocellulose membranes (0.2 µm pore size, Sigma) were pre-rinsed in methanol and deionized
water before use. 0.5 µl sample spots of were applied to the membrane and allowed to dry.
The membrane was then blocked in 4% (w/v) BSA in PBS for 15 minutes, washed in PBS and
incubated with a 1/25 dilution of antibody-conjugated gold nanoparticles in 1% (w/v) BSA in
PBS for 3 hrs at room temperature with gentle agitation provided by an orbital shaker. The
membranes were then rinsed with copious PBS and deionized water to remove unbound nanopar-
ticles and subjected to silver enhancement. This involves deposition of metallic silver upon gold
nanoparticles by the gold-catalysed reduction of Ag (I) ions by hydroquinone[126]. The washed
membranes were incubated in a silver enhancement solution (British Biocell International) and
allowed to incubate at room temperature for 15-20 minutes.
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2.2.4 Peptide synthesis
Peptides can be readily synthesised using well-established solid phase methods developed by
Merriﬁeld [127]. In this approach, amino-acid monomers are sequentially incorporated into a
growing peptide chain, chemically tethered to a polymeric solid-phase support resin, by forma-
tion of an amide bond between amine and carboxylic acid groups. The free N-terminal amino
group of the resin-immobilised peptide reacts with excess activated ester derivative of the next
amino-acid to be incorporated into the growing peptide chain. Potential self-polymerisation of
the incoming amino-acid is prevented by temporarily blocking its N-terminus with a labile pro-
tecting group. Following amide formation, the N-terminus is subsequently deprotected, the resin
washed with solvent to remove excess by-products and reagents, and the cycle repeated for the
next amino-acid in the sequence. Other side-reactions during the synthesis are also prevented
by blocking potentially reactive amino-acid side-chains with protecting groups that can be easily
removed, under relatively mild conditions, at the end of the synthesis. This ensures that the
amides of the peptide backbone are exclusively formed between the N- and C-termini of the
amino-acids. Following completion of the synthesis, the peptide is released (cleaved) from the
resin and the side-chain protecting groups simultaneously removed. Whilst this procedure can
produce short peptides (<25 residues) of good purity, longer peptides or peptides of complicated
sequence can pose more synthetic problems and recombinant bacterial expression systems are
typically are a more suitable method of production.
C-terminal amide substrates and bis-substrate derivatives for Src (IYGEFKKKGGGIYGE-
FKKK, IYGEFKKK) were synthesised by automated solid-phase peptide synthesis on an Ap-
plied Biosystems ABI 431A synthesiser. MBHA Rink Amide resin (0.63mmol/g loading) and
Fmoc-protected amino acids were obtained from Novabiochem. All other solvents were obtained
from AGTC Bioproducts (Hessle, UK). All peptides were synthesised on a 0.1 mmol scale with
10-fold molar excess of amino-acid monomers using HOBt/HBTU/DIEA activation in NMP
and 1 h coupling times. Fmoc groups were deprotected using 20% piperidine in NMP. Following
synthesis, the resin was washed with copious DMF and DCM in a fritted separating funnel and
treated with a standard peptide cleavage/deprotection cocktail (5 mL triﬂuoroacetic acid (TFA)
:triisopropylsilane (TIS) :water (95:2.5:2.5)) for 3 h. The volume of TFA was then reduced
under a stream of N2, the crude peptide precipitated and washed with ice-cold diethylether.
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The peptides were puriﬁed by C-18 reverse phase HPLC using linear elution gradients of wa-
ter:acetonitrile containing 0.1% TFA.
2.2.5 Enzyme assays
Enzyme reactions consisted of 10 units of Src, 10µM peptide substrate and 200 µM ATP in
a total volume of 10 µl. The reaction mixture was incubated for 1.5 h at 30 0C prior to
transfering an aliquot to a solution of antibody-coated gold nanoparticles (1 nM) to reach
peptide concentrations from 4 pM - 500 nM.
2.2.6 Dynamic light scattering
Dynamic light scattering (also known as photon correlation spectroscopy) measures ﬂuctuations
in scattering intensity over time for particles in solution undergoing Brownian motion. Applying
a correlation function in conjunction with the Stokes-Einstein equation:
RH =
kT
6piηD
(2.1)
where RH is the hydrodynamic radius, T is temperature, D the diﬀusion coeﬃcient, and k
the Boltzmann constant, relates these ﬂuctuations to the hydrodynamic radius of the particles,
providing information on the size and size distribution of the particle dispersion. The hydro-
dynamic radius of the particles were measured on a Malvern Zetasizer Nano- ZS with a 633
nm laser source. All solutions were ﬁltered using a 0.22 μm Millex®GS MF-Millipore MCE
Membrane ﬁlter (Millipore, UK) prior to analysis in 1 cm pathlength disposable polysyrene
cuvettes at room temperature. Measurements were collected with a minimum of 12 runs and
analysed using the manufacturer's software. Nanoparticle concentrations were on the order of
10 pM, diluted in PBS.
2.2.7 UV-visible absorption spectroscopy
UV-visible absorption spectroscopy measures the attenuation in intensity of incident light upon
passing through a sample analyte relative to a standard. This attenuation is due the absorption
of light by the sample arising from electronic transitions to an excited state and/or scattering
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phenomena. The concentration of the analyte can be related to its absorbance, A, at wavelength
λ using the Beer-Lambert law, Aλ = log(I0/I) = ελ.c.l, where I0 is the intensity of light
transmitted through a reference, I is the intensity of light which has passed through the sample,
ελ is the molar extinction coeﬃcient (M−1cm−1), l the absorption path-length and c is the
molar concentration of the absorbing species. UV-visible absorption spectra were carried out at
room temperature on a Perkin Elmer LAMBDA 25 specrophotometer (Waltham, MA) using 1
cm path-length quartz cuvettes.
2.3 Results and Discussion
2.3.1 Peptide synthesis
HPLC of the bivalent and monovalent control peptides revealed the presence of a single dominant
elution peak suggesting the presence of a homogeneous synthesis product (Figure 2.4). The
puriﬁed peptides were further analysed by MALDI mass spectrometry, yielding dominant m/z
peaks at 1012 and 2177 for the control and bivalent peptides respectively corresponding to the
predicted [M+H+] masses (Figure 2.5).
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Figure 2.4: Reverse phase HPLC traces of bivalent (A) and monovalent control (B) peptides.
The single dominant peaks reﬂect the high purity of the peptide products ( > 98 %)
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Figure 2.5: MALDI spectra of synthetic Src substrate peptides H2N-IYGEFKKK-CONH2 (A)
and H2N-IYGEFKKKGGGIYGEFKKK-CONH2 (B)
2.3.2 Antibody conjugation to gold nanoparticles
2.3.2.1 Electrostatic assembly
Preliminary studies were carried out to investigate the feasibility of producing AuNP-antibody
conjugates based on direct electrostatic assembly through interaction with positively charged
amino acid side chains on the antibody and the NP citrate stabilising layer [128]. This was
achieved by titrating the antiphosphotyrosine antibody against 40 nm AuNPs (1 nM) at the
IgG isoelectric point to determine the minimum amount of antibody required to stabilise the sol
against electrolyte-induced aggregation initiated by the addition of NaCl to a ﬁnal concentation
of 100 mM. Whilst this is an appealing method owing to its relative simplicity it is limited by
i) the inability to control the antibody orientation on the surface; ii) large quantities of protein
are required to passivate the AuNP surface which may limit cost-eﬀectiveness and iii) the non-
covalent nature of the assembly may render the conjugate susceptible to ligand exchange and
dissociation [101][124]. Nonetheless, initial eﬀorts were focussed on preparing antibody-AuNP
conjugates by electrostatic assembly. Antibody concentrations ≤8 µg/ml failed to provide any
signiﬁcant stabilisation, as indicated by a complete ﬂocculation of the nanoparticles and loss of
colourimetric signal (Figure 2.6). Even relatively high concentrations of antibody (24 µg/ml)
failed to provide complete stabilisation, as supported in the UV-Vis absorbance spectra (Fig-
ure 2.7, A), suggesting that the nanoparticles may only be partially surface passivated at this
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Figure 2.6: Salt-induced aggregation of 40 nm gold nanoparticles to determine minimum amount
of antibody required to stabilise the colloid. The loss of colouration at lower antibody con-
centrations reﬂects complete particle ﬂocculation in the presence of sodium chloride. Higher
concentrations of antibody aﬀord slightly greater resilience against particle ﬂocculation, but the
colour change from red to blue, relative to the control, suggests insuﬃcient particle stabilisation.
concentration. In consideration of the poor stabilisation aﬀorded by this method of biocon-
jugate preparation, the ambiguous surface orientation of the antibody and the large amounts
of antibody required for nanoparticle stabilisation (i.e. poor cost-eﬀectiveness) an alternative
approach was investigated.
2.3.2.2 Dithiol-mediated assembly
In order to aﬀord better control of antibody-nanoparticle orientation and to provide a more
reproducible conjugation protocol, an alternative immobilisation procedure was utilised. This
involved site-specic conjugation of dithiol appended cross-linker to the carbohdyrate moieties of
the antibody Fc region via hydrazide-aldehyde coupling and directed orientation of the antibody
on the nanoparticle surface aﬀorded by the bidentate thiol-gold interaction [124]. Assembly of
the thiol-appended antibodies on the gold nanoparticle surface was conﬁrmed from UV-vis
spectra which demonstrated a small red-shift in the plasmon absorption peak from 525 nm to
529 nm (Figure 2.7, B), presumably due to a change in the nanoparticle local dielectric constant
upon antibody binding [129]. In addition, no appreciable broadening in the absorption spectra
at wavelengths > 600 nm was observed, suggesting that the addition of antibody did not induce
substantial nanoparticle aggregation. Dithiol-mediated antibody assembly was also veriﬁed by
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dynamic light scattering, revealing an increase in hydrodynamic radius from 45 nm to 75 nm
relative to the uncoated citrate-stabilised AuNPs, consistent with the formation of an antibody
layer on the nanoparticle surface. The bioconjugated gold nanoparticles did not show any visible
sign of macroscopic aggregation for at least 1 month under storage at 4 0C.
Figure 2.7: UV-vis absorption spectra of antibody AuNP conjugates prepared by electrostatic
absorption (A) and dithiol-mediated assembly (B) (normalised to plasmon absorption peak)
Figure 2.8: Dynamic light scattering analysis of citrate- and antibody-coated 40 nm AuNPs
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Figure 2.9: UV-vis absorbance spectra of antibody-modifed AuNPs in the presence of diﬀerent
concentrations of pY-BSA (normalised to plasmon absorption peak)
2.3.3 Bioconjugate binding to phosphorylated model proteins
In order to ensure that the antibody-AuNP conjugates retained functional antigen binding
properties, control experiments were conducted using phosphotyrosine-conjugated BSA (pY-
BSA) as a model phosphoprotein. It was anticipated that the protein should be able to act as an
eﬃcacious cross-linking molecule and cause aggregation of the anti-phosphotyrosine conjugated
AuNPs, resulting in an observable change in the UV-vis absorption spectra due to interparticle
plasmon coupling. To test this hypothesis, the antibody-AuNP conjugate was incubated with
pY-BSA at diﬀerent concentrations spanning three orders of magnitude. Under these conditions,
no extensive red-shift, peak broadening or reduction in signal intensity was observed in the UV-
vis absorption spectra, inconsistent with the model of pY-BSA-induced particle aggregation
(Figure 2.9).
This behaviour can be explained by several potential mechanisms. For instance, the in-
herrent pY-BSA structure and distribution of antibody-accessible phosphotyrosine residues on
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the protein may render it unsuitable to eﬀectively cross-link the antibody-AuNPs due to steric
constraints. Unfortunately the manufacturer could not provide further information concerning
the BSA-pY structure nor degree of phosphotryosine loading on the carrier protein (personal
communication). In addition, it may be possible that the particles do aggregate to some extent
upon binding to pY-BSA, however the interparticle separation remains too great to aﬀect a sub-
stantial colourimetric response [130]. Alternatively, the failure to observe a colourimetric signal
may be due to a loss of antibody function upon immobilisation on the nanoparticle surface.
To investigate this ﬁnal possibility, serial dilutions of pY-BSA or kinase reaction prod-
ucts were spotted on nitrocellulose membranes and incubated with the antibody-AuNP con-
jugate, followed by extensive washing and catalytic silver deposition on any surface-bound
nanoparticles[131]. Successful binding was indicated by the development of grey spots on the
membrane where the antigen was deposited. The protocol enabled rapid and convenient visual
assessment of antibody binding and could detect down to 320 ng/ml (5 nM) concentrations
of pY-BSA antigen, corresponding to 2.5 pg of total protein within 20 min. Furthermore, the
sharp localisation of the enhancement restricted to the area in which the antigen was spotted
and antigen concentration dependent enhancement intensity is indicative of the speciﬁcity of
the antibody binding. A more quantitative analysis of antibody-AuNP binding may be aﬀorded
through the use of CCD based detection in conjunction with a more reproducible method of
delivering uniform sample spots to the nitrocellulose membrane.
In summary, these results suggest that antibody-AuNP conjugates are functional and can suc-
cessfully bind to target phosphoproteins however, the phosphotyrosine-conjugated BSA molecule
was unable to elicit any colourimetric response in the nanoparticle system or produce any obvi-
ous signs of macroscopic precipitation. Although the pY-BSA molecule was unable to initiate
nanoparticle aggregation, its structure should diﬀer substantially from the kinase substrate
peptides, thus it was assumed that these negative observations should not necessarily provide
unequivocal evidence that the kinase substrate peptides designed here would not be able to
initiate interparticle cross-linking.
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Figure 2.10: Nitrocellulose membrane based immunodetection of phosphorylated proteins using
silver deposition enhancement. A) Duplicates of diﬀerent concentrations of phosphotyrosine BSA
were immobilised on nitrocellulose membranes prior to treatment with antiphosphotyrosine-
conjugated AuNPs and silver enhancement. B) Alternatively, aliquots of kinase reaction mix-
tures, containing diﬀerent concentrations of the bivalent substrate peptide, kinase and +/- ATP
were transferred to the membrane, followed by antibody-AuNP binding and silver enhancement,
suggesting successful phosphorylation of the peptide and antibody binding.
60
2.3.4 Protein kinase activity assays
The bivalent peptide substrate for Src was incubated with the kinase followed by addition of
aliquots of the enzyme reaction to the antibody-conjugated gold nanoparticles to reach diﬀerent
peptide conentrations. The reaction mixtures were then analysed by UV-vis absorbance and
DLS. Should the peptides elicit particle aggregation in the presence of kinase activity, it was
predicted that this could be readily detected by UV-vis absorbance and an increase in particle
hydroynamic radius or particle sedimentation. The normalised absorption spectra did not reveal
any changes in the plasmon absorption peak position or peak broadening as a function of peptide
concentration in the case of both the bivalent and monovalent control peptide, suggesting that
no signiﬁcant particle aggregation had taken place. This was also reﬂected by DLS experiments
which did not provide any evidence of increase in particle hydrodynamic radius or aggregation.
It was observed however, that higher concentrations of peptide could induce a subtle red-shift
in the nanoparticle absorption spectra after ∼3 hr, with the plasmon absorbance peak shifting
from 532 nm to 534 nm (Figure 2.11). This occured in both the case of the bivalent and control
peptide substrates or control experiments in the absence of ATP, suggesting that this was likely
due to non-speciﬁc eﬀects. For instance, the peptides or enzyme may displace the nanoparticle-
bound antibodies or surface-adsorbed BSA molecules resulting in a decrease in colloidal stability
over time. This may be due to some of the antibodies being bound to the nanoparticle surface by
more labile electrostatic absorption mechanisms as opposed to the higher-aﬃnity thiol-directed
immobilisation. In addition, the presence of a cluster of thiol-bearing cysteinyl residues within
the Src kinase domain, as indicated by the sequence of the protein and high resolution crystal
structure [132], may contribute to this inherrent instability by providing a high aﬃnity binding
motif to compete for the AuNP surface.
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Figure 2.11: AuNP absorbance spectra following addition of Src kinase reaction aliquot in the
presence (A) or absence (B) of ATP. The analagous evolution of signal in both cases reﬂects the
fact that this is not due to an enzyme-speciﬁc process.
2.4 Conclusions and Future Work
This chapter has described the attempt to develop novel peptide substrates which can selectively
induce the aggregation of antibody-modiﬁed gold nanoparticles in response to protein kinase ac-
tivity to provide a convenient colourimetric signal. Whilst it was not possible to demonstrate
successful detection of kinase activity in this case, several important lessons were learned here
which helped guide the development of additional nanoparticle-based enzyme detection strate-
gies, as detailed in the remainder of this thesis.
As part of the goal of realising rapid, simple and convenient nanoparticle-based enzyme
detection it was concluded that the approach explored here would not provide an appropriate
solution for kinase screening for several reasons. For instance, whilst the original intention of
this study was to introduce peptides which could circumvent the use of immobilised peptides to
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aﬀord more physiological substrate analogues and simplicity in assay design, this approach neces-
sitated reasonably sophisticated antibody modiﬁcation procedures, thus the predicted beneﬁts
of the system were counteracted by the complexity and cost introduced by additional biocon-
jugation steps. In addition the assay is reliant on a complex interplay of numerous biomolecule
interactions with varying aﬃnities and rates of association/dissociation. Some of the potential
interactions may indeed be antagonistic to the operation of the assay - for example, the bis-
phospho peptide may be unable to mediate interparticle immuno-aggregation due to its local
concentration favouring an intraparticle interaction (i.e. binding to two antibodies on the same
nanoparticle) or steric repulsion providing too great a kinetic barrier and preclude interparticle
collisions required to initiate particle aggregation [88]. Furthermore, the number of potential
interactions at play presents a broad and complicated parameter space to optimise and may
result in narrow windows of operation in terms of reagent concentrations. For example, a previ-
ously reported AuNP-based lactamase sensor, using a similar cross-linking principle, exhibited
a profound dependence on nanoparticle concentration and only exhibited enzyme-responsive ag-
gregation behaviour within a AuNP concentration range spanning from 1.3-3 nM [133]. Other
designs could be investigated to increase the probability of peptide phosphorylation driving par-
ticle aggregation by increasing the eﬀective valency of the peptide. For example, as opposed
to the use of a bifunctional peptide, capable of cross-linking a maximum of two individual
nanoparticles, a dendrimeric peptide structure containing multiple potential binding sites could
provide a greater propensity to initiate large-scale particle aggregation and could be realised by
conjugating an appropriate peptide substrate to a branched dendrimer core [134].
The observed particle red-shifts at longer time scales were likely due to non-speciﬁc interac-
tions and/or displacement of the nanoparticle passivating protein layer. This could be limited
using more robust ligand coating shells less susceptible to ligand exchange, such as UV cross-
linked diacetylene motifs, which could be subsequently conjugated to the antibody molecules
[100]. In order to minimise the possibility of some of the antibodies becoming bound to the
nanoparticle surface via labile electrostatic absorption as opposed to thiol-mediated binding, it
may also be possible to develop alternative cross-linking agents and chemoselective antibody
coupling strategies. For example, the nanoparticles could initially be derivitised with a homob-
ifunctional hydrazide followed by selective coupling to the oxidised antibody [65].
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It could, however, be possible to greatly simplify the system, remove the need for sophis-
ticated bioconjugation and abrogate the need for phospho-speciﬁc antibodies. For example,
the peptides designed here could be used in conjunction with streptavidin-coated AuNPs and a
γ−biotin derivative of ATP [13], with kinase activity resulting in bis-biotinylation of the peptide
and subsequent streptavidin-AuNPs cross-linking. This could provide a convenient homogeneous
assay without need for additional nanoparticle separatory or puriﬁcation steps, assuming that
the enzyme can utilise the biotinyl-ATP analogue and that the size of the nanoparticle aggregates
are commensurate with an appreciable colourimetric response.
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Chapter 3
Preparation of Peptide-Coated
Semiconductor Nanocrystals For
Kinase Sensing and Cellular
Imaging
3.1 Introduction
Chapters 3 and 4 detail the development of an alternative approach to protein kinase biosensing
based on the use of photoluminescent semiconductor nanocrystals as FRET donors, with Chap-
ter 3 describing the development of new QD-peptide conjugates and Chapter 4 demonstrating
their utility in the detection of two prototypal tyrosine kinases, Src and Abl [114, 108].
Fluorescence-based detection oﬀers several advantages compared to absorbance measure-
ments due to increased sensitivity and the fact that FRET sensing can aﬀord a dual param-
eter response (i.e. changes in both donor and acceptor ﬂuorescence intensity at two distinct
wavelengths). This provides a robust ratiometric signal which assists in accounting for inter-
experiment variability, to which single-wavelength absorption or ﬂuorescence measurements are
particularly prone.
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3.1.1 Overview of experimental design
Numerous QD assays for enzymatic activity are based on energy transfer owing to the numerous
beneﬁts associated with QDs as energy transfer donors. These assays, however, have been largely
restricted to hydrolytic enzymes, such as proteases and bacterial β-lactamases [4, 135, 65, 136].
Here, enzymatic activity drives the dissociation of an energy transfer acceptor, such as an or-
ganic dye or gold nanoparticle quencher, from the immediate vicinity of the QD resulting in
changes in non-radiative energy transfer from the QD to acceptor. Nonetheless, hydrolytic
enzymes are but a small sub-class of the diverse families of enzymes which mediate protein
post-translational modiﬁcations. For example, there are a wide range of enzyme-mediated mod-
iﬁcations mediated by enzymes which operate with fundamentally diﬀerent mechanistic details
to hydrolytic enzymes. Such enzymes catalyze the addition of modifying groups to various
amino acid side chains to impart new functionality upon the target protein. It is thus diﬃcult
to readily reconﬁgure QD assays for hydrolytic enzymes to examine other important enzyme-
mediated modiﬁcations without fundamental redesign of the system. Therefore, it was sought
to develop a new class of assay which could be applied to study enzyme reactions which result
in the formation of covalent substrate adducts, as opposed to hydrolytic cleavage events.
As a model system and owing to their central role in disease, it was chosen to develop an assay
towards measuring the activity of protein tyrosine kinases which employed the photophysical
properties of QDs.
The QD is conjugated to a protein kinase substrate peptide by means of a hexahistidine
(His6) motif which self-assembles on the ZnS surface by virtue of a multivalent interaction
aﬀorded by consecutive imidazole side-chains [137]. This QD-peptide conjugate is acted upon by
a corresponding protein kinase in the presence of ATP, resulting in phosphorylation of tyrosine
residues. This is subsequently detected by means of immunorecognition-driven binding of a
complementary anti-phosphotyrosine antibody conjugated to ﬂuorescent dye molecules (Figure
3.1). Provided that the QD core is in suﬃciently close proximity to the dyes, energy transfer
(FRET) can take place, as manifested by an increase in dye-speciﬁc emission and decrease in
QD-speciﬁc emission. It was predicted that several features of this system should be conducive
to eﬃcient FRET. For instance, bioconjugate preparation based on self-assembly of the peptides
directly on the surface of the nanocrystal ensures that the overall dimensions of the complex
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Figure 3.1: QD-based FRET immunoassay for tyrosine kinase activity (one peptide/QD shown
for clarity). Dye-labeled antibody recognises the kinase phosphorylated peptide, resulting in QD-
dye energy transfer and is manifested as a simultaneous increase and decrease in dye-speciﬁc
and QD-speciﬁc emission respectively.
are relatively compact (Figure 3.1, 1)), enabling the acceptor ﬂuorophores to come within close
proximity of the QD FRET donor to favour eﬃcient FRET - in contrast to other means of
QD-bioconjugate preparation which rely on bulky streptavidin or polymer coatings [61, 4]. In
addition, each QD FRET donor can potentially interact with multiple FRET acceptors due to
the multivalent nature of the QD-peptide assembly and the antibodies' capacity to conjugate to
several acceptor dyes, aﬀording a high overall acceptor:donor ratio and enhanced energy transfer
(Figure 3.1, 2)) [3].
3.1.2 Peptide conjugated quantum Dots
Since the ﬁrst demonstrations of antibody labeling of semiconductor nanocrystals (quantum
dots, QDs) for cellular imaging in 1998 [138], signiﬁcant technical advancements have been
made to enable the conjugation of a variety of other biological molecules. Improved synthetic
procedures in the literature and the availability of commercial sources of QDs with a range
of surface coatings has greatly facilitated the development of biological applications of QDs.
As part of the eventual goal of utilising QD bioconjugates for FRET-based enzyme sensing,
it was sought to investigate a range of approaches to prepare peptide-conjugated QDs. This
chapter describes the solubilisation and bioconjugation of CdSe/ZnS core-shell QDs to a range
of synthetic peptides corresponding to protein kinase substrate sequences.
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Endowing QDs with the biological and chemical functionality of peptides results in the
ability to use their unique photoluminescent properties to interrogate a wide range of cellular
and biological processes. For example, NIR-emitting QDs modiﬁed with cell-targeting peptides,
such as the cyclic-RGD integrin binding motif, can be used for non-invasive in vivo small animal
imaging of tumor vasculature [139], oligoarginine-tagging results in cellular internalisation of
QDs and coating with enzyme-hydrolyzable peptide sequences aﬀords a range of proteolytic
sensing systems [64, 3, 38, 140]. Several strategies to successfully interface QDs with peptides
have been explored, each with associated advantages and limitations. We sought to develop a
peptide:QD conjugation procedure which;
 could be applied to commercially available sources of QDs in order to circumvent compli-
cated synthesis protocols requiring potentially hazardous precursors;
 did not require the use of cross-linking agents to simplify subsequent puriﬁcation;
 did not require substantial expertise in chemical synthesis;
 aﬀorded reasonable control of QD:peptide stoichiometry with predictable peptide orienta-
tion on the QD surface;
 produced compact conjugates of relatively small hydrodynamic radii, owing to ﬁnal in-
tended applications in for energy transfer (FRET) based sensing.
To this end, commercially available CdSe/ZnS QDs were rendered water soluble by base-assisted
ligand exchange with a hydrophilic low molecular weight thiol and subsequently modiﬁed with
peptides using a self-assembly strategy. Steady-state and time-resolved spectroscopy in addition
to gel-electrophoresis were implemented to characterise the photoluminescence and structural
details of the QD-peptide systems. In addition, as part of ongoing work and in order to validate
the biological activity of these QD-peptide systems, some of these conjugates were applied to a
simple immunoassay and cell-imaging.
Nanobioconjugates prepared by self-assembly procedures are highly advantageous compared
to covalent coupling methods owing to associated speed and convenience. Quantum dots have
been subject to modiﬁcation with peptides using various self-assembly procedures. For in-
stance, proteins appended with a sequence of contiguous positively charged amino acid residues
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or cationic leucine zipper domains can self-assemble on anionic QDs by simple electrostatic as-
sociation [141] [38], however the generality of this method may be limited, particularly in the
case of inherently cationic peptides and proteins. In addition, dative bonding between thiol
groups of cysteine residues and surface sulphur atoms has been used to conjugate protease
substrates and cell-penetrating peptides on QD surfaces [142] [143]. This does not provide a
high-degree of control over biomolecule:QD stoichiometry and requires exposing the peptides to
high concentrations of organic solvent and would therefore be a poor conjugation strategy for
some proteins with sensitive three-dimensional structure. It has also been demonstrated that
oligohistidine-terminated peptides and recombinant proteins can self-assemble upon the surface
of dihydrolipoic acid (DHLA) capped QDs due to a multivalent metal-aﬃnity coordination of
histidine imidazole groups to surface Zn atoms [144, 145, 117]. This is a persuasive option as
the conjugation step is performed in aqueous solution and aﬀords some degree of control over
ﬁnal QD:biomolecule ratio. A drawback of this method is the reliance on prior solubilisation
of the QDs using DHLA - a reasonably complicated multistep procedure requiring high concen-
trations of QD and reduced DHLA [41]. Nonetheless, hexahistidine-appended proteins can also
self-assemble on anionic phospholipid-coated nanocrystals, as suggested in FRET studies using
recombinant ﬂuorescent proteins [144]. It was unclear, however, whether the assembly process
was due to a direct interaction between the protein and inorganic shell of the QD or through
the hydrophilic surfactant coating. An alternative method of conjugation has been described
based upon divalent cation-dependent assembly of hexahistidine-tagged proteins on QDs coated
with a carboxylic acid functionalised stabilising polymer [146]. Similarly, QDs can be derivitised
with a nickel-triacetic acid motif, to which hexahistidine-tagged biomolecules can bind through
high-aﬃnity chelation [147]. These are appealing methods owing to their simplicity, but are
reliant upon bulky polymeric stabilisers, resulting in a large hydrodynamic radius which would
preclude eﬃcient FRET [46].
To develop new QD-peptide conjugates for enzyme sensing, and in consideration of the
available options, a modiﬁed conjugation method was sought which could utilise simple-self
assembly in conjunction with hydrophilic quantum dots prepared by straightforward chemical
derivitisation to aﬀord stable biomolecule-nanocrystal conjugates. Here, commercially available
red-emitting (605 nm emission maximum) CdSe/ZnS core/shell QDs were rendered water soluble
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by simple base-promoted ligand exchange with a hydrophilic low molecular weight thiol and
further modiﬁed with hexahistidine-appended peptides (Figure 3.2). These bioconjugates can
be applied to simple immunoassays and new methods to screen enzyme activity, as detailed in
the remainder of this thesis.
Figure 3.2: Schematic representation of experimental strategy to prepare peptide-QD conju-
gates. Hexahistidine-mediated assembly of peptides on ZnS surface of mercaptopropionic acid
(MPA) stabilised QDs. Hydrophobic stabilising surfactant is replaced with MPA by means of
base-promoted ligand exchange. Multivalent imidazole-ZnS interactions provided by the con-
secutive histidine residues aﬀord stability against peptide dissociation.
3.2 Materials and Methods
3.2.1 Quantum dots (QDs)
All solvents and reagents, unless stated were obtained from Sigma-Aldrich. Core/shell CdSe/ZnS
quantum dots (605 nm emission maximum, 1.0 µM stock) in decane were obtained from Invitro-
gen. Prior to use, the QDs were transferred to a polypropylene centrifuge tube and ﬂocculated
with the addition of a 5-fold volume of 3:1 MeOH/iPrOH. The QDs were centrifuged at 6000 g
for 2 min, the supernatant decanted and the QDs resuspended in CHCl3 to a ﬁnal concentra-
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tion of 100 nM. QDs were visualised during benchtop manipulations under 365 nm illumination
provided by a hand-held UV lamp.
3.2.2 MPA exchange
10 ml of CHCl3 and 500 µl of mercaptopropionic acid (MPA) were added to 1 g of tetramethyl
ammonium hydroxide pentahydrate (TMAH) in a 50 mL polypropylene centrifuge tube, mixed
vigorously by vortexing for 30 s and allowed to stand for 30 min at room temperature. The
two phase mixture resulting from the TMAH water of crystallisation was centrifuged (4000 g,
5 min) and the lower organic phase (approx. 90 % of the total volume) decanted. 1 ml of
100 nM QDs in CHCl3 was added to the organic phase and the mixture allowed to stand at
room temperature protected from light for 40 hr. Initially, the solution exhibited homogeneous
photoluminescence under UV illumination. Following incubation, however, the QDs formed
distinct photoluminescent droplets ﬂoating on the surface of the CHCl3 phase. The droplets
were washed three times with 10 ml CHCl3 and extracted with 10 ml of 10 mM borate buﬀer
(pH 9.0) with the QDs seen to transfer completely into the aqueous phase. The aqueous phase
was then subjected to three cycles of ten-fold concentration/dilution using 10 KDa MWCO
ultraﬁltration units (Millipore) at 4000 g for 10 min. The MPA-capped QDs were then stored
in the dark at 40C. The concentration of the QDs was determined from the absorption intensity
of the absorption onset peak in the UV-visible absorption spectra (596= 650,000 M-1cm-1,
manufacturer's information).
3.2.3 Synthesis of octylamine-modiﬁed polyacrylic acid (O-PAA)
An amphiphilic polyacrylic acid (PAA) derivative was prepared using a previously reported
procedure [148]. 2.16 g of polyacrylic acid (Sigma, free acid form, 2000 g/mol, supplier's in-
formation) and 2.85 g of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)
was dissolved in 20 mL of DMF in a 100 mL round bottom ﬂask equiped with a magnetic stir
plate. 1.6 mL of octylamine was added dropwise over the course of 10 minutes and the clear
solution was mixed overnight at room temperature under nitrogen. This molar ratio results in
40 % octylamine substitution of the total PAA carboxylic acid groups. The progress of the re-
action was monitored by thin layer chromatography and ninhydrin staining. When the reaction
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was complete, as indicated by a negative ninhydrin test, 75% of the DMF was removed using
a centrifugal evaportation system (Genevac HT-4, Gardiner, NY). The residue was transferred
to a polypropylene centrifuge tube and mixed with h 10 mL of acetone and 25 mL water. The
precipitated product was recovered by centrifugation (4000 g, 5 min) and washed with 25 mL
water three times. The solid was dissolved in 40 mL ethyl acetate in a 100 mL round bottom
ﬂask with gentle heating at 400C. 6.1 g TMAH in 25 mL H2O was added and the mixture
stirred for 15 min. The aqueous layer was collected using a separating funnel and acidiﬁed to
pH 2.0 using 2N HCl. The cloudy precipitate was collected by centrifugation (3000 g, 5 min)
and washed with 50 mL H2O three times. The residue was redisolved in 50 mL ethanol and
dried under vacuum at 600C to aﬀord a pale yellow sticky solid. 100 µl of a 100 nM QD so-
lution in chloroform was added to 1ml of a 1 mg/ml solution of O-PAA in CHCl3, the solvent
evaporated and the QDs redispersed in 1 ml 50 mM borate buﬀer (pH 9.6). The solution was
passed through a 0.45 µm syringe ﬁlter (Millipore) and puriﬁed by ultraﬁltration though a 50
KDa cut-oﬀ centrifugal ﬁltration device (Millipore).
3.2.4 DHLA synthesis
Dihydrolipoic acid was prepared by reduction of thiotic acid [41]. 3 g of thiotic acid (Sigma) was
dissolved in 60 mL aqueous 0.25 M sodium bicarbonate in a 100 mL round bottom ﬂask on ice.
600 mg of sodium borohydride (NaBH4) was added in 10 mg aliquots over a 10 min period with
continuous stirring of the solution. After one hour, the yellow solution had turned colourless. 50
mL of ethyl acetate was added and the mixture acidiﬁed to pH 1.0 using 2 N HCl. The organic
phase was collected using a separatory funnel, dried with magnesium sulphate, ﬁltered and the
solvent removed under vacuum to aﬀord a pale yellow oil which was stored at -200C before use.
3.2.5 Peptide synthesis
All reagents were obtained from Novabiochem. Peptides based on known substrate sequences for
Src (Ac-IYGEFKKKHHHHHH-CONH2) and Abl (H2N-AEIYAAPFAEEHHHHHH-CONH2),
and complementary tyrosine/phenylalanine substitution peptides (Ac-IFGEFKKKHHHHHH-
CONH2, H2N-AEIFAAPFAEEHHHHHH-CONH2) were prepared using a standard Fmoc cou-
pling strategy on an Aapptec Apex 396 combinatorial peptide synthesiser. 1 mM stock solu-
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tions of Fmoc side-chain protected amino acid monomers and equimolar quantities of HOBt
were dissolved in DMF before use. 1 hr coupling reactions employed 4-fold excess of amino
acid monomer using N, N'-diisopropylcarbodiimide as a condensing agent. Deprotection steps
and cleavage reactions were conducted as previously described. Peptides were puriﬁed to > 98
% by C-18 semi-preparative HPLC (Varian, Walnut Creek, CA) using linear elution gradients
of H2O/acetonitrile containing 0.1 % TFA. The identity of the peptides was veriﬁed by liquid
chromatography/mass spectrometry (LC/MS) (Agilent 1100, Santa Clara, CA).
Peptide Sequence Molecular Weight
(Src) Ac-IYGEFKKKHHHHHH-CONH2 1876.1 gmol-1
(SrcF) Ac-IFGEFKKKHHHHHH-CONH2 1860.0 gmol-1
(Abl) H2N-EAIYAAPFAEEHHHHHH-CONH2 2032.2 gmol-1
(AblF) H2N-EAIFPFAEEHHHHHH-CONH2 2016.2 gmol-1
Table 3.1: Predicted masses of peptides used throughout this study
3.2.6 Peptide conjugation to QDs by metal-aﬃnity driven self-assembly
1 mM stock solutions of peptide were prepared in deionized water and stored at -200C before use.
Stock solutions were diluted in 10 mM sodium borate buﬀer (pH 9.6) to 1µM. 20 µl aliquots of
100 nM MPA-capped QDs were incubated with diﬀerent volumes of peptide to achieve diﬀerent
molar ratios of peptide:QD, from 0-50:1 and the solutions mixed rapidly to ensure homogeneity.
3.2.7 Agarose gel electrophoresis
1% (w/v) agarose gels were prepared by dissolving routine use agarose powder (Sigma) in Tris-
acetate-EDTA (TAE buﬀer, 40 mM Tris base, 20 mM acetic acid, 1 mM EDTA, pH 7.8) with
microwave-assisted heating. 20 μl aliquots of MPA-capped QDs (100 nM) in 10 mM sodium
borate (pH 9.6) were incubated for 1 hr with diﬀerent volumes of peptide solution (1 μM) to
achieve peptide:QD ratios ranging from 0-50:1. Glycerol (100%) was then added to the solutions
to reach a ﬁnal concentration of 5% (v/v) prior to well loading. The peptide conjugates were
then run on agarose gels in TAE buﬀer for 30 mins at 10 V/cm and imaged under 365 nm
illumination.
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3.2.8 UV-Vis absorbance spectroscopy
UV-visible absorption spectra were carried out at room temperature on a Perkin Elmer LAMBDA
25 specrophotometer (Waltham, MA) using 1 cm path-length quartz cuvettes.
3.2.9 Steady-state photoluminescence
Steady-state photoluminescence emission spectra were recorded at room temperature on a Jobin
Yvon FluoroMax-4 Flourimeter using 50 µl quartz three-window ﬂuorescence cuvettes. 400 nm
excitation and 5 nm excitation/emission The acquired spectra were corrected for variations in
lamp and detector eﬃciency with ﬁles from Jobin Yvon. Alternatively, ﬂuorescence intensity
measurements were carried out in black 96-well ﬂuorescence microplates (Cornig, Rochester,
NY) on a Gemini XS microplate reader (Molecular Devices, Sunnyvale, CA).
3.2.10 Measurement of quantum yield
Quantum yields (QY ) of QDs were calculated relative to absorption-matched dilutions of sulphorho-
damine 101 in ethanol as a reference (QY = 0.90) according to:
QYQD = QYR × IQD
IR
× AR
AQD
× η
2
QD
η2R
where I is the integrated luminescence intensity, A is absorbance intensity at the excitation
wavelength (400 nm) and η is the refractive index of the QD and reference (R) solutions [149].
3.2.11 Time-resolved photoluminescence
Time-resolved single photon counting (TCSPC) provides information on the excited state life-
time of ﬂuoroscent molecules. In essence, an ensemble of ﬂuorophores is excited with a pulsed
excitation source and the arrival time of single photons emitted from the sample is recorded, with
the process repeated many times to build a histogram of photon arrival times. In many scenarios
the excitation pulse-width is on a comparable time scale as the sample life-time and, as such,
the observed decay is a convolution of the excitation pulse (instrument response function) and
the sample impulse response. Deconvolution is achieved by considering the excitation pulse as a
series of inﬁnitely sharp δ-functions of diﬀerent amplitudes resulting in a measured signal which
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can be expressed as sum of many individual decays with diﬀerent amplitudes and start times.
In practice, the instrument response function can be readily measured by recording the decay of
a zero-lifetime sample, such as a scattering sample of dilute colloidal silica. TCSPC can provide
insight into the photoluminescent lifetimes of QDs, which exhibit lifetimes relatively longer than
those of standard organic ﬂuorophores (10-100 ns) and size- and wavelength-dependent multi-
exponential decay proﬁles, due to the inherent QD size distribution and dynamic non-radiative
decay channels [150][151][152].
Time-resolved PL decays were collected on a Jobin Yvon Fluorolog TCSPC spectrophotome-
ter using a 200-ps 440 nm LED modulated at 1 MHz as an excitation source on samples with an
absorbance of < 0.1 at 440 nm. 10,000 count coaxial delay of 65 ns, time-to-amplitude converter
(TAC) range of 50 ns was employed. The instrument response function decay curve was mea-
sured using a dilute aqueous solution of colloidal silica (Ludox). Average sample lifetimes were
calculated by ﬁtting the measured decays to a convolution of the instrument response function
and a double-exponential decay. Average lifetimes (τ¯), were calculated according to [149]:
τ¯ =
α1τ
2
1 + α2τ
2
2
α1τ1 + α2τ2
3.2.12 QD conjugation to antibodies for phosphoprotein detection and
cell labeling
The puriﬁed B1 immunoglobulin binding domain of Streptococcal protein G (GB1), expressed
with an N-terminal hexahistidine tag was a gift from Ms Cheryl Goldbeck (Lawrence Berkeley
National Laboratory) [153]. In a ﬁnal volume of 100 µl, 50 nM QD-MPA in 50 mM borate buﬀer
(pH 9.0) was incubated with a 30-fold molar excess of GB1 for 30 min at room temperature.
Following which, excess GB1 was removed by 3 rounds of 10-fold concentration/dilution using a
50 kDa MWCO centrifugal ultraﬁltration unit (Millipore, 4000 g, 8 min) and resuspended in 50
µl PBS containing 0.1 % (w/v) BSA. An aliquot of monoclonal antiphosphotryosine (clone PT-
66, Sigma Aldrich) or anti-actin (clone YOL1/34, Abcam) was added to the QD-GB1 conjugate
(antibody:QD ratio 4:1) and incubated for 1 hr at room temperature and used without further
puriﬁcation.
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3.2.13 Heterogeneous immunoassay and cell labeling
3.2.13.1 Immunoassay
Nitrocellulose membranes (0.2 µm pore size, Sigma) were pre-rinsed in methanol and deionized
water before use. Serial dilutions of phosphotyrosine-modiﬁed BSA (Sigma) (0.5 µl) were spotted
on the membrane and allowed to dry for 1 min before blocking with 4 % (w/v) BSA in PBS
for 30 min. The membranes were then incubated with a 1 % (w/v)BSA-PBS solution of QD-
GB1-antibody (10 nM QD) for 2 hr at room temperature followed by washing with copious
PBS.
3.2.13.2 Cell labeling
Mouse embryonic NIH 3T3 ﬁbroblasts (ATCC) were grown to 70% conﬂuence on poly-D-lysine
coated glass-bottom microscopy dishes (MatTek, Ashland, MA) in high-glucose DMEM con-
taining 10 % fetal bovine serum. The cells were rinsed with copious PBS and ﬁxed with 4%
(w/v) paraformaldehyde in PBS for 10 min and permeabilised/blocked with 0.1% (v/v) triton-
X100/4% BSA (w/v) in PBS for 30 min. The ﬁxed cells were incubated with 10 nM QD-GB1-
antitubulin for 3 hr at room temperature. Images were acquired on an Olympus IX-81 inverted
microscope equipped with a 75W Xe lamp, a PLAPON 60x 1.45NA oil-immersion lens, and an
Andor iXon+ EMCCD. Exposure times were 100 ms and all images were captured under identi-
cal camera conditions. Images were acquired through a Cy5 ﬁlter set using a Xe lamp and DAPI
excitation ﬁlter (Semrock). Images were collected and analyzed using Slidebook 4.1 (Intelligent
Imaging Innovations). All images were background corrected using a cell-free area from the ﬁrst
image and set to identical dynamic intensity ranges with a linear contrast adjustment.
3.3 Results and Discussion
3.3.1 Peptide synthesis
The HPLC-puriﬁed and lyophilised peptides were subjected to LC-MS, yielding molecular ion
peaks within 1 mass unit of their predicted molecular weights thus verifying their identity (Figure
3.3).
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Figure 3.3: LC-MS analysis of peptides used in this study. Y axes correspond to relative signal
intensity.
3.3.2 Phase transfer of QDs
It is possible to perform biomolecule conjugations on commercially available water-soluble QDs
using various covalent cross-linkers or streptavidin/biotin interactions, however these approaches
have certain limitations with respect to energy transfer-based sensing. Covalent cross-linking
to polymer-coated QDs often involves extensive processing and puriﬁcation procedures, increas-
ing the likelihood of loss of material. Although streptavidin-biotin mediated self-assembly of
nanoparticle conjugates using streptavidin-coated QDs is reasonably straightforward, the large
dimensions of streptavidin contributes to a considerable distance between the QD core and
acceptor dye and may preclude high-eﬃciency FRET. Thus, it was sought to use an approach
based on peptide self-assembly directly to the ZnS surface of the QD in order to abrogate the use
of cross-linkers, facilitate puriﬁcation and minimise the ﬁnal hydrodynamic radius of the conju-
gate. To this end, we aimed to transfer commercially available QDs, soluble only in non-polar
organic solvents, into aqueous solution. This was achieved by base-assisted ligand exchange of
the native QD surfactant coating with MPA (Figure 3.4). This procedure employs TMAH to
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deprotonate the MPA thiol which in turn enhances its reactivity towards the ZnS surface [37].
Quantum yield and colloidal stability are often substantially diminished when thiols are used to
solubilise QDs [154].
Dithiols can provide improved colloidal stability, however high concentrations of QD and
dithiol are required and such procedures are not commensurate with straightforward bench-
top manipulations [41]. The approach used here, however, could be conducted under ambient
conditions, and yielded stable QD dispersions which did not show any signs of macroscopic
aggregation when stored at room temperature or at 40C over a period of several months and
high-speed centrifugation at 30,000 g for 10 min did not result in any visible pelleting, verifying
that the QDs were well dispersed. Furthermore, whilst photooxidation may lead to instability
in some mercaptocarboxylic acid coated QDs [155], the MPA-capped QDs did not show any
nonticeable propensity to aggregate under ambient lighting conditions over time. The eﬃciency
of the phase-transfer was typically c.a. 85% as determined UV-vis absorbance.
Figure 3.4: Base-assisted phase transfer of quantum dots to aqueous solution
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Figure 3.5: Phase transfer of MPA-coated CdSe/ZnS QDs (605 nm emission max) from CHCl3
(lower) to aqueous buﬀer (upper) (50 mM borate, pH 9.0)
3.3.3 Optical properties of MPA-capped QDs
UV-vis spectroscopy indicated that the position of the absorption onset 596 nm did not change
in position between the MPA-capped QDs or the as-received hydrophobic surfactant-coated
QDs. In light of this observation, it was assumed that the molar extinction coeﬃcients of the
MPA and TOPO capped quantum dots at the ﬁrst exciton were equivalent and was used for all
subsequent concentration calculations. As a comparison, an aliquot of QDs was rendered water
soluble by encapsulation within an interdigitating amphiphilic polymer, octylamine-modiﬁed
polyacrylic acid (O-PAA) [148] and exhibited a subtle red-shift in the absorption onset to 601
nm, possibly reﬂecting partial leakage and delocalisation of the exciton wave function into the
polymer shell (Figure 3.6) [29]. There was a slight decrease in quantum yield in the case of
the MPA-capped QDs from 0.55 to 0.44 and a slight decrease in absorption intensity at shorter
wavelengths < 400 nm, relative to surfactant-coated hydrophobic QDs, consistent with previous
reports (Figure 1.6) [37]. This may reﬂect speciﬁc electronic eﬀects upon thiol absorption to the
QD surface the loss of some population of QDs during the phase transfer process [156].
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Figure 3.6: UV-Vis absorbance of surfactant coated QDs in CHCl3, MPA-capped QDs in aque-
ous buﬀer (10 mM borate, pH 9.6) and amphiphile-coated QDs (40 % octylamine modiﬁed
polyacrylic acid, O-PAA) in buﬀer (normalised to ﬁrst exciton absorption peak)
Steady-state photoluminescence suggested that the emission maximum peaks, centered ∼605
nm, and emission peak widths of the QDs with diﬀerent coatings to provide solubility in aqueous
solvent remained essentially unchanged from the hydrophobic QDs (TOPO coated) in chloroform
(Figure 3.7). Again, some red-shift in emission maximum was observed in the case of the
polymer-stabilised nanocrystals, in line with other studies which have used amphiphile-based
coating procedures and possibly arises due to increased exciton delocalisation [29] [157].
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Figure 3.7: Emission peak maximum and peak width at half maximum (FWHM) for QDs with
diﬀerent surface coatings. TOPO nanocrystals were dispersed in CHCl3and MPA, DHLA and
octylamine-modiﬁed polyacrylic acid (O-PAA) were dispersed in 50 mM borate buﬀer (pH 9.0)
3.3.4 Peptide conjugation to quantum Dots
Earlier studies have suggested that the surface of MPA-capped QDs can be further derivitised
with biological molecules, such as amine-terminated ssDNA, by standard EDC/NHS coupling
[37]. It is questionable that amide formation is the exclusive associative mechanism of biocon-
jugate formation as incubation of MPA-capped QDs with FRET acceptor-labeled DNA, in the
absence of coupling agents, results in rapid QD-dye energy transfer, suggesting an appreciable
degree of non-speciﬁc DNA/QD binding [158]. Furthermore, EDC/NHS has limited capacity
for site-selective coupling and renders biomolecules with both carboxy and amine groups sus-
ceptible to excessive cross-linking and precipitation [123]. In comparison, self-assembly driven
conjugate formation with the absence of covalent bond formation provides a straightforward
alternative for the formation of well-deﬁned nanoscale architectures [159] [160]. The peptides
employed here were designed to contain an appending hexahistidine sequence (His6) which has
been demonstrated to self-assemble upon the surface of DHLA-coated ZnS surfaces of QDs [161].
In order to determine a strategy to expedite peptide conjugation to QDs, initial experiments
were carried out to determine whether the native surfactant coating of the QD could be replaced
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directly with His6 peptide using a 9:1 (v:v) pyridine:DMSO co-solvent system with a 500-fold
molar excess of peptide, predisolved in DMSO. This approach has been demonstrated in the
case of replacing TOPO (trioctylphosphine oxide) with cysteine-rich phytochelatin-related pep-
tides on QD surfaces [162] [163]. Here, however, this resulted in QD precipitates which could
not be resuspended in aqueous buﬀers (e.g. PBS, borate) suggesting that peptides were unable
to suﬃciently replace the native hydrophobic coating under these conditions. Thus, a two-step
procedure was employed, involving initial phase-transfer of the QDs to aqueous solution followed
by peptide modiﬁcation. Whilst this approach is slightly more time consuming, it can provide a
means to control peptide loading density on the surface of the QD and results in less ambiguity
in the ﬁnal peptide:QD stoichiometry[3].
3.3.4.1 Peptide conjugation to MPA-capped QDs: preliminary Studies
Peptides with sequences based on known substrates for the protein kinases Src and Abl were
used in this study. In addition, peptides analogues with tyrosine/phenylalanine substitutions
were also synthesised for negative controls in enzyme assays. Initial studies with Src substrate
sequences indicated that incubating QDs (100 nM) in 10 mM borate buﬀer (pH 9.0) with a large
excess of peptide (500-fold) would lead to immediate formation of nanoparticle precipitates which
were insoluble in aqueous buﬀer. In case of the possibility of the resultant peptide-conjugate
having inherrently reduced solubility in aqueous buﬀer, DMSO (10% v/v) was included in the
solution, however, this also lead to nanoparticle aggregation. Therefore, the molar ratio of
peptide to QD was systematically varied from 0-100:1 in 10-fold increments to investigate its
eﬀect on QD colloidal stability. Similarly, at all ratios examined, all failed to produce stable QD
dispersions. Addition of other additives and non-ionic surfactants, such as polyethylene glycol
and Tween-20, to colloidal nanoparticle systems has been shown to enhance stability during some
ligand-exchange reactions by providing additional steric stabilisation and slowing the kinetics of
incoming ligand binding [124][164][165]. Pre-incubation with 0.1% Tween-20 (v/v) for 30 min
prior to peptide addition also failed to produce stable QD dispersions. In light of the possibility
that the monovalent nature of the MPA thiol-ZnS interaction could inﬂuence the absorption
kinetics of the peptide and stability of the system, the MPA-QDs were further derivatised with
the divalent thiol, DHLA [149]. A 1000-fold excess of DHLA (1 mM in 10 mM borate, pH 9.0)
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was incubated with MPA-QDs for 24 hr at room temperature in the dark, followed by removal
of excess ligand by repeated ultraﬁltration. The DHLA-capped QDs also did not provide stable
dispersions following peptide incubation under the same conditions as the MPA-QDs, providing
support that the thiol-ZnS interaction was not an underlying factor in determining the stability
of the peptide-conjugate.
3.3.4.2 Eﬀect of pH on conjugate stability
The Src substrate sequences used in these studies contained three tandem lysine residues. At pH
9.0, these residues are likely to be in their ionized form (i.e. NH3+ ) and the peptide will have
appreciable cationic character. As cationic polyelectrolytes and peptides can cause ﬂocculation
of electrostatically-stabilised anionic nanoparticles through charge-screening [11] [166], the eﬀect
of pH on conjugate formation was sytematically studied as it is likely to aﬀect the charge of the
peptide [80]. Aliquots of 10 μM peptide solution were added to MPA-QDs in 10 mM borate buﬀer
at a range of pH values from 9.0 - 11.0 in polypropylene centrifuge tubes. After incubation for
1 hr at room temperature, the samples were centrifuged at 16,000 g for 5 min to indicate if QD
ﬂocculation had occured, as indicated by QD pelleting visible by eye. The photoluminescence
intensity in the samples was equivalent across the pH range, suggesting that the QD structure
had not been compromised by the pH. These experiments did not reveal any QD pelletting at
pH values > 9.6 suggesting that either the peptide had stably associated with the QD surface or
that the elevated pH somehow inhibited the assembly of the conjugate. Thus, gel electrophoresis
was employed to further characterise the peptide-QD assembly process.
3.3.5 Agarose gel electrophoresis of peptide-QD conjugates
Agarose gel electrophoresis is a commonly-used analytical technique used in molecular biology to
separate biological macromolecules based on size and charge. Nanoparticles can also be subjected
to gel electrophoresis to provide low-resolution information on changes in hydrodynamic radius
and charge in response to surface modiﬁcation [167][168][169]. Whilst electrophoresis cannot
provide precise molecular information on the nature of the nanoparticle surface ligands, it is a
rapid and convenient technique with modest sample requirements. Src substrate peptides were
incubated with MPA-QDs at molar ratios from 0-50:1 at pH 9.6 for 30 min prior to loading
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into 1 % (w/v) agarose gels. Under 365 nm illumination, concentration-dependent changes in
electrophoretic mobility were observed as a function of peptide:QD ratio, with the mobility of
the QDs being retarded in the presence of peptide compared to MPA-QDs alone, consistent
with peptide assembly on the surface of the QD. Some saturation behaviour was exhibited,
with no further changes in conjugate mobility at peptide:QD > 30:1, suggesting saturation
of potential peptide binding sites (Figure 3.8). This behaviour was also recapitulated in the
case of the peptide substrate and substrate analogue for Abl, suggesting a similar peptide: QD
stoichiometry. This is consistent with other measurements of peptide:QD ratios in the case of
DHLA-capped nanocrystals which suggested much lower experimental loading densities than
those predicted by theory [170]. This was attributed to the existence of a ﬁnite number of His6
binding sites on the QD surface as opposed to a continuous interface to which the peptides can
form a homogeneous closely-packed monolayer. The fact that the two QD-peptide conjugates
exhibit similar electrophoretic mobilities, despite the fact that they theoretically should have
diﬀerent overall charges (pIs of 10.4 and 6.0 for the Src and Abl substrates respectively) may be
attributed to masking of charged groups by counterions (EDTA, borate etc) in solution, leading
to both of the peptide-QD conjugates having similar net charges.
Dynamic light scattering was also employed to determine changes in the hydrodynamic ra-
dius of the QD following peptide conjugation however, due to limiting amounts of experimental
material, the observed scattering count rates were too low for reliable cumulants ﬁtting (not
shown). Time-resolved photoluminescence experiments, however, provided some additional ev-
idence that peptide binding was occuring on the nanocrystal surface due to observations of
changes in the QD excited state lifetime upon exposure to hexahistidine-appended biomolecules
(vide infra). [171].
3.3.6 Time-resolved photoluminescence
Electron-hole pair recombination rates have been shown to be highly sensitive to QD surface
chemistry in some instances due to the relatively high surface area to volume ratio associated
with nanoscale materials [66] [172]. Thus, the eﬀect of the peptide coating on QD radiative
lifetime was therefore investigated by nanosecond TCSPC. The water soluble biomolecule-coated
nanocrystals exhibited modiﬁed decay proﬁles (see below for ﬁtted lifetime data), relative to
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Figure 3.8: Representative agarose gel electrophoresis of QDs coated with varying ratios of pro-
tein kinase substrate peptide to QD ((A) Ac-IYGEFKKK-H6-CONH2; (B) EAIYAAPFAEE-
H6-CONH2). The direction of migration in both cases was towards the cathode, consistent
with both of the conjugates having net negative charge. The lack of further changes in elec-
trophoretic mobility at peptide:QD ratios >30:1 suggests saturation of peptide binding sites on
the nanocrystal surface.
hydrophobic QDs in chloroform and MPA-capped QDs in aquesous solvent. There are several
plausible explanations for this observation; ﬁrstly whilst the ZnS shell surrounding the CdSe
core helps in the exciton conﬁnement, imperfections in the shell and the surfactant coating
play an additional role in passivating the QD. Replacing the native surfactant coating with
thiols may increase the non-radiative recombination rate by acting as additional hole-traps
[37]. Alternatively, the diﬀerences in decay rate may be a reﬂection of diﬀerences in solvent
environment, with water molecules providing an additional decay pathways. Addition of peptides
and GB1 (30 per QD) further inﬂuenced the decay kinetics relative to QD-MPA, increasing the
slow component of the decay (Table 3.2). Furthermore, addition of BSA (0.01% w/v) which
can assemble on QD surfaces, presumably by electrostatic interaction, to QD-MPA dramatically
altered the decay proﬁle [173, 99]. These results support the hypothesis that the peptides used in
this study can assemble on the surface of the QDs and tentatively suggest that the His6 peptides
and BSA may be acting to suppress additional decay pathways by either passivating surface
trap sites or by providing a protective shield against solvent interactions with the QD surface.
Changes in the lifetime of red-emitting (605 nm emission maximum) QDs in basic aqueous
solution has been measured as a function of hydrophilic ligand coating, using a range of thiol
stabilisers, such as mercaptoacetic acid (MAA), mercaptosuccinic acid (MSA) and dihydrolipoic
acid (DHLA) [174]. These experiments revealed only modest diﬀerences in lifetime between the
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QDs with diﬀerent ligand-coatings (< 1 ns) compared to the observations here. Surprisingly,
there are scant references in the literature to how biomolecule coating can inﬂuence the QD
excited state lifetime, and these preliminary studies should warrant further investigation into
how peptides and proteins of diﬀerent sequence and/or charge can eﬀect the photoluinescent
properties of QDs.
Figure 3.9: Time-resolved photoluminescence decay proﬁles water soluble QDs with various
biological surface coatings (c.a. 20 nM QD-biomolecule, 10mM borate buﬀer pH 9.0).
Coating τ¯ (ns) τ1 (ns) α1(%) τ2 (ns) α2 (%)
TOPO ( in CHCl3) 11.8 3.0 43 13 57
MPA 14.2 2.3 52 16.1 48
Abl 16.9 2.8 43 18.6 57
AblF 17.2 2.8 42 18.8 58
Src 16.2 2.9 47 18.0 53
SrcF 15.5 2.9 51 17.7 49
BSA 18.6 3.2 36 20.1 64
GB1 14.9 3.2 41 16.5 59
Table 3.2: Average photoluminescence lifetime (τ¯), separate lifetime components (τ1, τ2 ) and
relative amplitudes (α) after ﬁtting data to a biexponential decay function.
3.3.7 Conﬁrmation of peptide-QD bioactivity by cell imaging
In order to provide evidence that the QD-peptide conjugates retain biological activity to pro-
vide useful biosensing reagents, a straightforward and rapid binding assay was developed. To
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this end, the QD-GB1 conjugates were allowed to bind to anti-phosphotyrosine or anti-tubulin
antibodies and used in a simple nitrocellulose blotting assay or in vitro imaging experiment
using phosphotyrosine-BSA and formaldehyde-ﬁxed cells respectively as model target proteins.
Using a self-assembly strategy as a means to prepare the antibody-QD conjugate is straight-
forward compared to the use of other commonly heterobifunctional covalent crosslinkers and
ensures that the antibody binding site is not compromised during the QD labeling procedure
[175] [147]. This approach is analagous to the use of a similar engineered antibody-binding
adaptor protein which assembles on QD surfaces through simple electrostatic interactions [176].
The use of hexahistidine-based self-assembly, however, ensures that the QD-GB1 interaction
here is less sensitive to extremes of pH and/or ionic strength. These experiments revealed se-
lective binding to phosphoproteins or tubulin respectively, as revealed by UV-illumination and
ﬂuorescence microscopy respectively, providing a simple control experiment and strong support
that the MPA-capped QDs can be conjugated to biomolecules by metal-aﬃnity self-assembly
without loss of biological function (Figure 3.10). The subsequent goal was to demonstrate that
the additional peptide-QD conjugates prepared here can be applied to the detection of protein
kinase activity and is detailed in the following chapter.
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Figure 3.10: Composite bright-ﬁeld & ﬂuorescence image of tubulin immunostaining in mouse
NIH-3T3 cells (A) and dot-blot QD immunoassay (B) (two-fold serial dilutions of phosphotyro-
sine BSA 2.0 mg/ml - 31.125 µg/ml and 0 mg/ml negative control)
3.4 Conclusions and Future Work
This goal of this work was to successfully conjugate peptides to hydrophilic quantum dots, with
view to developing key components of a novel protein kinase biosensing assay. A range of protein
kinase peptide substrates and substrate analogues were successfully conjugated to water soluble
MPA-capped QDs by means of a straightforward self-assembly procedure. This yielded QD-
peptide conjugates with stoichiometries of c.a. 30:1 as suggested by agarose gel electrophoresis.
The QD photoluminescence emission characteristics were shown to be sensitive to the pep-
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tide/protein environment as revealed by TCSPC, presumably due to passivation of defect sites
on the nanocrystal surface [29]. The biological activity of the QD-peptide conjugates was vali-
dated in principle using a simple heterogeneous immunoassay and through cell imaging. These
immunosensing reagents may provide a basis for further development of nanoparticle-based
imaging studies and form part of an ongoing collaboration with the Lawrence Berkeley National
Laboratory. This is the ﬁrst demonstration that commercially available quantum dots can be
rendered water soluble using mild benchtop manipulations and conjugated to biomolecules us-
ing a simple self-assembly strategy. This should provide a basis for the rapid development of
other biomolecule-QD systems. It was not possible to determine useful additional parameters
concerning the peptide:QD interaction (dissociation constant, precise peptide: QD stoichiom-
etry etc), however, future studies could be focussed on addressing these issues. For example,
it may be possible to label the peptides with a FRET acceptor ﬂuorophore, titrate the labeled
peptide against a ﬁxed concentration of QDs and measure FRET eﬃciency as a function of
peptide:QD ratio. Occupation of all available peptide binding sites on the QD surface should
result in eventual saturation of FRET eﬃciency as a function of peptide:QD; the point at which
this is reached should reﬂect an approximate value for maximum possible peptide converage
[177].
Building from this work, it was sought to apply these new QD-substrate peptide hybrid
bionanomaterials to the detection of protein kinases and other important enzyme systems, as
detailed in Chapter 5 and 6.
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Chapter 4
Protein Kinase Actuated FRET in
Quantum Dot - Peptide
Bioconjugates
4.1 Background and Introduction
Having successfully demonstrated that peptides and MPA-capped QDs can form stable self-
assembling conjugates, it was sought to apply these hybrid nanomaterials to the detection of
protein kinase activity. The aim of this study was to demonstrate that QDs can be applied
in simple homogeneous FRET-based immunoassays for the detection of enzyme-mediated post-
translational modiﬁcations.
4.1.1 FRET-based QD immunoassays
There have been several demonstrations that quantum dots can be used in simple homogeneous
immunoassays using FRET-based detection. For example, various small-molecule haptens, such
as biotin and cortisol, have been conjugated to polymer-coated QDs which can subsequently be
recognised by dye-labeled antibodies resulting in QD-dye energy transfer. Such a system can be
employed in competitive binding assays [46]. This is a simple procedure but is limited by the
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use of bulky polymer stabilisers and the fact that competitive immunoassays are often diﬃcult
to optimise [178]. Nonetheless, it was possible obtain very large Förster radii (up to 8.4 nm)
with the QD-dye pairs used in this system, thus having great potential for long-range FRET.
Other competitive immunoassays have been reported based on the displacement of an acceptor
dye-labeled analyte analogue from a recombinant single chain antibody fragment bound to a QD
surface. Such a system has been applied to the detection of the explosive 2,4,6-trinitrotoluene
(TNT), which removes the quencher-conjugated analogue from the antibody binding site result-
ing in enhanced photoluminescence emission from the QD [179]. In order to achieve eﬃcient
FRET, it was argued that it was necessary to engineer such an antibody fragment to aﬀord short
interﬂuorophore distances. This, however, requires signiﬁcant development times to obtain an
appropriate antibody fragment [180]. Energy transfer between immunoassembled BSA-coated
and anti-BSA-coated CdTe QDs with diﬀerent emission wavelengths has also been suggested,
however inter-QD FRET is often problematic due to inevitable direct excitation of FRET ac-
ceptor QDs due to substantial overlap in both the donor and acceptor QD excitation spectra
and time-resolved measurements are essential to unequivocally demonstrate the extent of such
a FRET process [55] [181]. Whilst these are useful and sensitive detection systems, it is notable
that none of the reported FRET-based immunodetection methods have so far been developed to
detect dynamic biological stimuli, such as enzyme activity, but rather the static presence of an
analyte. Here, QDs are engineered to serve as FRET donors in an enzyme-responsive manner.
4.1.2 Experimental design
In considering the ubiquity of immunological-based detection methods in biology, medicine and
in in vitro assays, it was sought to develop a new simple and generic immuno-FRET proce-
dure for the detection of protein kinase activity. It was predicted that the photoluminescence
properties of QDs should render them ideal labels in FRET-based enzyme sensing due to the
straightforward ability to tune the QD emission to any spectral region, potentially from the UV
to IR, as to suit the user's end application. This, taken with the additional ability to eﬃciently
excite QDs at any wavelength below their emission maximum, should provide a straightforward
means to eliminate potential autoﬂuorescence interference.
Two new approaches were developed which were predicted to obviate the need for polymer-
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coated QDs and/or sophisticated recombinant antibody fragments. To this end, water soluble
QDs were conjugated to peptide substrates for the tyrosine kinases Src and Abl by metal-
aﬃnity mediated self-assembly [182] [62]. These conjugates were then treated with their respec-
tive tyrosine kinase in the presence of ATP, leading to enzymatic phosphorylation of tyrosine
residues. This was subsequently detected by means of a complementary FRET acceptor-labeled
full-length anti-phosphotyrosine antibody or an antibody fragment site-selectively labeled us-
ing chemoselective thiol-maleimide coupling (Figure 4.1) [183]. The resultant formation of a
diﬀusing QD-antibody immunocomplex was predicted to lead to substantially decreased spa-
tial separation between the QD and FRET-acceptor dyes and result in eﬃcient QD-dye energy
transfer. These two complementary approaches, based on full-length antibodies or antibody
fragments, were each predicted to oﬀer several unique beneﬁts. For example, dye labeling of
full-length antibodies using amine-reactive probes is a straightforward procedure and can yield
high dye:antibody loading densities [184]. Alternatively, antibody fragments (Fab' fragments),
consisting solely of the antigen binding region, are of substantially diminished molecular weight
relative to full-length antibodies and thus may have improved steric accessibility to target anti-
gens [185]. Furthermore, the use of site-selectively labeled antibody fragments aﬀords greater
predictability in terms of the structure of the ﬁnal antibody-dye conjugate, as unique thiol
groups within the antibody structure can be speciﬁcally addressed using chemoselective modi-
ﬁcation procedures and the diminished size of the macromolecule should be more conducive to
smaller interﬂuorophore distances and more eﬃcient FRET.
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Figure 4.1: Experimental design for protein kinase mediated FRET in peptide-QD im-
munoassemblies. Dye-labeled antibodies selectively bind to enzyme-mediated post translational
modiﬁcation sites, resulting in QD-dye energy transfer (FRET).
4.2 Materials and Methods
4.2.1 Preparation of QD-peptide conjugates
Puriﬁed substrate peptides and Y/F substitution controls were incubated with MPA-capped
quantum dots (prepared according to materials and methods described in Chapter 3), for 30
min at room temperature (30:1 peptide:QD) in 50 mM sodium borate buﬀer (pH 9.6). An
aliquot of a 1 % (w/v) BSA solution in PBS was then added to a ﬁnal concentration of 0.1 %
and the QDs exchanged into assay buﬀer (25 mM Hepes (pH 7.5), 10 mM MgCl2) using a 10
kDa molecular weight cut-oﬀ centrifugal ultraﬁltration device (Millipore). The inclusion of BSA
between 0.01-0.1 % (w/v) in the medium was necessary to prevent nanoparticle ﬂocculation in
the presence of MgCl2, presubably by aﬀording additional steric stabilisation against electrolyte
induced aggregation [186].
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4.2.2 Antibody Dye labeling
4.2.2.1 Alexa Fluor 647-NHS ester
Monoclonal anti-phosphotyrosine (clone PT-66, Sigma) was labeled with the amine-reactive N-
hydroxysuccinimidyl (NHS) ester of AlexaFluor 647 (Invitrogen, Carlsbad, CA). The antibody
was buﬀer exchanged into PBS (pH 7.4) by centrifugal ultraﬁltration to remove excess azide
from the storage solution and resuspended to a ﬁnal concentration of 1 mg/ml. Stock solutions
of dye (∼1300 g/mol, 4 mM) were prepared in anhydrous DMSO and stored at -800C before use.
The antibody was reacted with a 10-fold molar excess of dye for 1 hr at room temperature with a
ﬁnal DMSO concentration of less than 1% (v/v). Following the reaction, excess dye was removed
by repeated rounds of concentration/dilution in PBS by centrifugal ultraﬁltration until the ﬂow-
through no longer exhibited any dye-speciﬁc absorption at c.a 650 nm, as determined by UV-Vis
absorbance (note: gel ﬁltration using Sephadex®G-25 as size exclusion media could also be used
to remove excess dye. Dialysis against PBS using a 10K MWCO regenerate cellulose membrane
(Thermo Fisher Scientiﬁc, Rockford, IL), however did not aﬀord adequate dye-removal, even
after 24 hr). The ratio of dye:antibody was measured using the extinction coeﬃcient of a
typical IgG molecule (ε280 = 203, 000 M-1cm-1) [187] and that of the dye (650 = 239, 000
M-1cm-1) (Manufacturer's information) and the expression:
[IgG](M) =
[A280 − (A650 × 0.03)]
203, 000
dye : IgG =
A650
239, 000× [IgG]
where 0.03 is a correction factor to take into account dye-speciﬁc absorption at 280 nm. The
dye-conjugated antibody was stored in PBS (pH 7.4) containing 0.1 % (w/v) BSA at 40C before
use.
4.2.2.2 Alexa Fluor 647-maleimide
F(ab')2 fragments were prepared by partial proteolytic digestion of the native anti-phosphotyrosine
antibody using agarose-immobilised ﬁcin. The agarose-ﬁcin slurry was pre-equilibrated in 0.1 M
citrate buﬀer (pH 6.0) containing 1 mM cysteine and 5 mM EDTA for 30 min at room temper-
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ature before use. 50 µl of 2.2 mg/ml antibody was incubated with 2 ml of the enzyme-agarose
slurry and incubated overnight at 370C with gentle agitation provided by an orbital shaker. An
aliquot of the crude digest was subjected to non-reducing polyacrylamide gel electrophoresis and
the digest fragments visualised by coomassie staining (Imperial Protein Stain, Thermo Fisher
Scientiﬁc, Rockford, IL) to verify cleavage of the antibody. The digest mixture was puriﬁed by
incubation with agarose-immobilised protein A to remove Fc fragments of the antibody. The
disulphides in the hinge region of the F(ab')2 were reduced using 50 mM 2-mercaptoethylamine
in the presence of 10 mM EDTA at 370C for 90 min and the antibody fragments (Fab') puriﬁed
by centrifugal ultraﬁltration. The Fab' reduced thiols were then labeled with Alexa Fluor 647
C2maleimide (20-fold excess) overnight at 40C and the conjugate again puriﬁed by centrifu-
gal ultraﬁltration. The ratio of dye:Fab' was calculated by UV-vis absorption, using the Fab'
extinction coeﬃcient (280= 750,000M-1cm-1).
4.2.3 Enzyme reactions
Recombinant GST-puriﬁed Src (SignalChem, Richmond, Canada) and Abl (Calbiochem, La
Jolla, CA) tyrosine kinases were used throughout this study and stored as single-use aliquots at
-800C. GST-puriﬁed enzymes were chosen, as opposed to hexahistidine-tagged enzymes, in order
to avoid potential ligand exchange with QD-bound hexahistidine-terminated peptides. Stock
solutions of 10 mM ATP (adenosine 5´-triphosphate disodium salt, ≥ 99 % purity, Sigma) were
prepared in 10 mM HEPES, pH 7.5 and stored at -800C before use. Generic kinase reaction
buﬀer consisted of 25 mM HEPES (pH 7.5), 10 mM MgCl2 containing 0.1 % (w/v) BSA. The
buﬀer was passed through a 0.45 µm syringe ﬁlter (Millipore) before use and prepared fresh on
the day of experiment. 10 µl dilutions of enzyme were incubated with 10 µl of QD-substrate
peptide conjugates (60 nM) and 5 µl 1 mM ATP in polypropylene tubes for 1.5 hr at 300C.
The reactions were quenched by chelating free MgCl2 with the addition of 20 µl 50 mM EDTA
prepared in 25 mM HEPES (pH 7.5) for 10 min at 300C. A 4-fold molar equivalent of anti-
phosphotyrosine-AF647 (full-length IgG or Fab' fragment) to QD was added to the sample an
allowed to incubate for 30 min before recording photoluminescence spectra. The precise volume
of anti-phosphotyrosine-AF647 added was dependent on the concentration of the conjugate, as
determined by UV-vis absorbance.
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4.2.4 Inhibitor titration
Stock solutions (1 mM) of the broad spectrum protein kinase inhibitor, staurosporine (Cal-
biochem, La Jolla, CA) were prepared in anhydrous DMSO and stored at -200C before use.
Triplicates of 5 U of Abl (10 µl) and 10 µl of QD-peptide conjugate (30 nM) were incubated
with 10 µl of serial dilutions of inhibitor in 25 mM HEPES, 10 mM MgCl2, 0.1 % (w/v) BSA
for 30 min at room temperature in 384-well black microplates (Cornig, Rochester, NY), before
initiating the kinase reaction with the addition of 1 µl ATP (ﬁnal [ATP] = 12.5 µM ≈ KM
ATP). The reactions were incubated for 1 hr at 300C before quenching the enzyme reaction
with EDTA and antibody detection, as described. The photoluminescence and ﬂuorescence
emission intensities at 605- and 670 nm were measured on a DTX 800 multimodal plate reader
(Beckman Coulter, Fullerton, CA) with 400 nm excitation.
4.3 Results and Discussion
4.3.1 Fluorophore labeling
The use of QDs and acceptor ﬂuorophores with red-shifted emissions (i.e. > 600 nm) facili-
tates the rejection of biological autoﬂuorescence which tends to occur at shorter wavelengths.
In addition, in drug discovery, autoﬂuorescence originating from test compound libraries is a
common source of signal interference in ﬂuorometric assays. The ability of a molecule to absorb
and emit longer wavelength (i.e. red) light is largely a function of the degree of its conjuga-
tion. This necessary high degree of conjugation is not normally represented to a large extent in
typical compound libraries, therefore red-emitting dyes show notable advantages as a means to
reduce signal artefacts due to autoﬂuorescence [20]. Thus, considering their emission proﬁle, the
QD605-AF647 pair was determined to be a particularly suitable candidate for FRET sensing
(Figure 4.2).
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Figure 4.2: Normalised absorption (dashed line) and emission (solid line) spectra of QD605
(blue) and Alexa Fluor 647 (red)
This FRET pair also exhibits a large Förster distance of 71.5 Å, comparable to the ex-
ceptionally large distances observed with lanthanide-based donors (65-90Å [42]), rendering it
particularly suitable for energy transfer in large macromolecular assemblies [46][42]. As the
dimensions of typical IgG molecules (14.5 x 8.5 x 4.0 nm) are reasonably large with respect to
high-eﬃciency FRET regimes associated with typical organic dyes, the QD605-AF647 pair was
predicted to be conducive to eﬃcient E [119][188]) .
Two antibody labeling procedures were investigated. In the ﬁrst approach, the antibodies'
free amines were randomly targeted with an NHS ester-AF647 derivative (Figure 4.3), typically
providing an IgG:dye stoichiometry of 4-5:1 as determined by UV-vis absorbance. This degree
of labeling was decided upon based on maximising the number of FRET acceptors per IgG
whilst minimising overlabeling which could result in dye self-quenching and/or compromising the
antibody's antigen binding site [189]. Alternatively, in order to aﬀord dye:antibody conjugates of
better deﬁned structure and stoichiometry, the antibody's Fv antigen binding fragment was site-
selectively labeled using a thiol-reactive maleimide-derivative of AF647 (Figure 4.4), following
partial enzymatic digestion of the native IgG and mild reduction of the hinge-region disulphides
to expose free thiols for chemoselective ﬂuorophore conjugation. Antibody fragment generation
and puriﬁcation was conﬁrmed by SDS-PAGE and protein staining, revealing a single 100,000
KDa band after protein A puriﬁcation, corresponding to F(ab')2 (Figure 4.5). The ﬁnal yield
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of the Fab'-AF647 fragment was 30 %, as determined by UV/vis absorption.
Figure 4.3: NHS-AF647 labeling of IgG amines
Figure 4.4: Chemoselective maleimide-thiol labeling of Fab' thiols
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Figure 4.5: SDS-PAGE analysis of Ficin digestion reaction products illustrating the appearance
of a single ∼100,000 KDa band following puriﬁcation, consistent with the proteolytic generation
of the F(ab2)' fragment.
4.3.2 Protein kinase activity assays: steady state photoluminescence
Following addition of AF647-antiphosphotyrosine antibody to the kinase reaction mixtures,
containing ATP, enzyme, peptide-QD conjugate and EDTA, a concomitant increase and decrease
in photoluminescence emission at 670 nm and 605 nm respectively as a function of enzyme
concentration was observed for both Src and Abl. Furthermore, this behaviour was an ATP-
dependent process and was not observed in the case of QD-conjugates which employed non-
phosphorylatable Y/F substitutions in the substrate sequence, consistent with kinase-activity
dependent energy transfer (Figure 4.6). Under the experimental conditions here, the maximum
observed FRET eﬃciencies, E, where E = 1 − FDAFD , were 76 % and 45 % for Abl and Src
respectively. Considering the similar size of the two substrates (18 and 15mer peptides), it
is unlikely that the observed diﬀerences in FRET eﬃciency are due to diﬀerences in peptide
structure and overall D-A separation. However, it is possible that the two peptides may have
slightly diﬀerent assembly mechanisms and/or packing structure on the QD surface and may
99
Figure 4.6: Steady-state photoluminescence spectra following addition of FRET-acceptor an-
tiphosphotryosine. (A) Abl and (B) Src concentration-dependent FRET behaviour; ratiometric
limit of detection for Abl (C) and Src (D)
not necessarily have equivalent numbers of enzyme-accessible tyrosine residues, thus providing
a limit to the maximum-observed FRET eﬃciency. For example, the KKK motif, in addition to
the appending hexahistidine, in the Src substrate peptide may also inﬂuence the orientation of
the peptide on the QD surface as primary amines have some aﬃnity for ZnS [190]. Alternatively,
the observed discrepancies may reﬂect subtle diﬀerences in enzyme-substrate preference and/or
speciﬁc assay buﬀer requirements for maximum enzyme activity.
Plotting the emission intensity ratios (670 nm/ 605 nm) against enzyme concentration was
carried out to determine approximate limits of detection. A reaction mixture which omitted
ATP was chosen as a baseline control. This revealed detection of 0.33 nM (25 mU/µl) Abl
and 2.3 nM (11.25 mU/µl) Src (signal:background = 4). This sensitivity is commensurate with
other widely used kinase assays and other nanoparticle-enable detection technologies [191, 192,
193, 11, 194]. In addition, this method has signiﬁcant advantages over other nanoparticle-
based methods due to the fact that only a single biofunctional nanoparticle is required, as
opposed to a heterogeneous mixture of nanoparticles with diﬀerent biological coatings to provide
both enzyme-responsive and signal-transducing components. It was demonstrated here that by
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simply changing the peptide substrate sequence, diﬀerent kinases could be readily detected
without need of substantial redesign of the system. This suggests that the system here is
ﬂexible and may provide a universal assay platform to detect the activity of a range of unrelated
kinases. Furthermore, self-assembly of the conjugates also aﬀords greater simplicity in terms
of preparation an puriﬁcation. Finally, it should be possible to enhance the sensitivity of this
kinase detection system by means of the use of antibodies with higher dye loadings, thereby
increasing the ratio of acceptor to donor, or the use of dye-QD pairs with larger Förster radii,
thus increasing energy transfer eﬃciency.
4.3.3 Protein kinase activity assays: time-resolved photoluminescence
To further verify that enzyme activity was actuating energy transfer, the QD lifetime in the
presence of diﬀerent concentrations of kinase was investigated using TCSPC measurements
(Figure 4.7). QD-dye FRET should be manifested as a decrease in QD excited state lifetime.
These experiments revealed a decrease in average lifetime as a function of enzyme concentration,
in an ATP-dependent manner, consistent with the model of speciﬁc protein kinase activity
actuated FRET.
Figure 4.7: Time resolved photoluminescence emission traces of Abl reactions in presence of
FRET-acceptor labeled antibody. Average lifetimes, τ , were obtained from ﬁtting the data to a
biexponential decay.
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Figure 4.8: Time resolved photoluminescence emission traces of Src reactions in presence of
FRET-acceptor labeled antibody. Average lifetimes, τ , were obtained from ﬁtting the data to a
biexponential decay.
4.3.4 Optimisation of antibody:QD ratio
The eﬀect of antibody concentration on FRET eﬃciency was investigated to ascertain whether
there was an optimum antibody:QD ratio and in order to avoid utilising the antibody in excess to
improve overall cost-eﬀectiveness. Therefore phosphorylated QD reaction products (200 mU/µl
Abl) were incubated with diﬀerent amounts of antibody to achieve diﬀerent ﬁnal antibody:dye
ratios, the photoluminescence spectra recorded and the 670 nm/605 nm emission ratio recorded.
Saturation behaviour was observed at ratios > c.a 4:1 (Figure 4.9). This possibly reﬂects steric
crowding eﬀects on the QD surface as only a ﬁnite number of antibodies (14.5 x 8.5 x 4.0 nm) will
be able to pack around the central QD (c.a. 4 x 9.4 nm, manufacturer's information), however,
given the limited information on the precise structural details of the QD-peptide conjugate, it
is diﬃcult to quantitatively model the QD-antibody interaction and its implications to FRET.
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Figure 4.9: Eﬀect of antibody:QD on energy transfer; (left) Steady state photoluminescence
spectra; (right) 670 nm/605 nm emission intensity ratio. The asymptote reached at ratios >4:1
antibody:QD suggests saturation of the QD surface, providing an upper limit to the number of
antibodies per QD required to elicit the maximum signal response.
4.3.5 Gel electrophoresis of kinase reaction products
Enzymatic phosphorylation of the QD peptide coating should lead to a change in surface poten-
tial due to the increased negative charge imparted by the phosphate group. It was predicted that
the electrophoretic mobility of the QD should change following phosphorylation and that this
could be veriﬁed by agarose gel electrophoresis [13]. Abl reaction mixtures (200 mU/µl) with
inclusion or ommission of ATP and/or the antiphosphotyrosine antibody were run on agarose
gels. From these observations, there was no discernable diﬀerence in electrophoretic mobility
between reactions which included or omitted ATP. This may be due to BSA binding to the
surface of the QDs and masking of any subtle electrochemical eﬀects that may inﬂuence over-
all electrophoretic mobility. The addition of the antiphosphotyrosine antibody was predicted
to result in a retardation in electrophoretic mobility of the peptide-coated QDs owing to the
substantially increased size of the resultant immunocomplex, provided that the immunorecog-
nition is not compromised within the gel matrix in the presence of an applied external electrical
ﬁeld. Some band broadening was observed in this case, tentatively suggesting that there may be
some heterogeneity in the QD-antibody interaction e.g. diﬀerent antibody:QD stoichiometries,
resulting in a range of QD-antibody complexes with diﬀerent electrophoretic mobilities.
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Figure 4.10: Agarose gel electrophoresis of Abl kinase reaction mixtures
4.3.6 Measure of Assay Robustness (Z'-factor)
In order to determine whether the assay could have potential as a high-throughput screening
tool, a quantitative measure of assay reliability was sought. One such parameter used to validate
the quality of high-throughput screens is the Z'-factor. This is a dimensionless coeﬃcient which
reﬂects the assay signal's dynamic range, data variation and reliability in identifying statistically
signiﬁcant hits from a compound library screen [195]. It is deﬁned using the means, µ, and
standard deviations, σ, of the positive (p) and negative (n) controls:
Z ′ = 1− 3× (σp − σn)| µp − µn |
Thus, Z' takes values between 0 and 1, with assays with Z' = 1 being 'perfect' and Z' values
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> 0.5 being considered to have excellent potential in HTS. The applicability of the QD kinase
assay to HTS was determined by carrying out Abl reactions, as described, at ﬁxed concentration
(200 mU/µl) for positive and negative (phenylalanine/tyrosine substitution) controls (n = 10)
and recording the photoluminescence spectra. The intensities at 605 and 670 nm were converted
to a ratio 670/605 and the means and standard deviations calculated (Figure 4.11, Figure 4.12).
This provided Z ′ values of 0.75, suggesting that the assay may be suitable for HTS applica-
tions. Equipment limitations prevented larger scale analysis of Z ′ in a genuine high-throughput
context, however, automated liquid handling systems capable of dispensing many hundreds of
experimental replicates into microplates should provide even more conﬁdent Z ′ values to further
validate this assay as a drug-discovery tool.
Figure 4.11: Determination of Z'-factor from PL spectra of Abl kinase QD reactions; Y/F
negative control (left); positive control (right), 200 mU/µl Abl
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Figure 4.12: 670/605 nm emission intensity ratios derived from steady-state photoluminescence
data used to calculate Z ′- factor. 10 independent experiements were conducted which employed
either the Abl cognate substrate (black squares) or the non-phosphorylatable phenylalanine
substitution (red circles) conjugated to the QD FRET donor.
4.3.7 Staurosporine Inhibition
As the assay appeared to show potential in HTS, further tests were carried out to investigate
whether it could be applied to quantitatively detect enzyme inibition. To this end, the broad
spectrum kinase inibitor, staurosporine, was incubated with Abl prior to initiating the kinase
reaction with ATP [196]. Inhibitor compounds libraries in HTS are typically pre-dissolved in
DMSO, with a ﬁnal solvent concentration of 0.5-1.5 % and, furthermore, Staurosporine itself is
only sparingly soluble in aqueous solution [197] . Thus it was necessary to test the tolerance
of the QD-peptide conjugates to DMSO at a commensurate concentration. At concentrations
of at up to at least 25 % DMSO, there were no observable changes in either colloidal stability
or photoluminescence properties of the peptide-QD conjugates, suggesting that the system was
compatible with the use of low concentrations of polar organic solvents.
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Figure 4.13: Structure of the ATP binding site competitor, staurosporine
Staurosporine is a microbial alkaloid which acts as a competitive ATP binding-site inhibitor
(Figure 4.13) [198]. As such, it is necessary to conduct assays at subsaturating concentrations
of ATP, typically within an order of magnitude of the KM. Preliminary studies were thus car-
ried out to ﬁnd appropriate concentration range in which to test the sensitivity of the assay
to Staurosporine by performing kinase reactions in the presence of diﬀerent amounts of ATP.
This provided an apparent KM value of 12.0 µM; consistent with previously reported literature
values of 12-18 µM [111]. Kinase reactions were then carried out in the presence of diﬀerent
concentrations of staurosporine and phosphorylated QDs detected as described. Plotting the
670/605 nm ratio against [staurosporine] revealed dose-dependent sigmoidal behaviour, as pre-
dicted for the case of speciﬁc enzyme inhibition. This provided a staurosporine IC50value (i.e.
half maximal inhibitory concentration) of 100 nM; comparable to previously reported literature
values of 76 nM generated using a ﬂuorogenic peptide / protease-coupled kinase assay [111].
This provides strong evidence that the assay developed here may have utility in the quantitative
determination of potential inhibitor potency and may serve as a drug discovery tool.
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Figure 4.14: ATP apparent KM determination (left) and Staurosporine dose-response curve
(right). Sigmoidal response is consistent with speciﬁc enzyme inhibition (error bars represent
standard error of the mean (n = 3)).
4.3.8 Investigation of other assay formats
It is possible to consider a number of potential assay designs, with variations in the arrangement
of peptides, antibody, QDs and dye. One of the fundamental design criteria is that QD-dye
distances should be minimised as to favour eﬃcient energy transfer. To this end, it was sought
to develop an alternative to the use of relatively large-sized native IgG which would allow smaller
interﬂuorophore distances to be accessible. The use of site-selectively labeled Fab' (i.e. antigen
binding) fragments was predicted to be a suitable alternative phosphotyrosine recognition moiety
and oﬀer several advantages compared to the use of full length IgG molecules. For instance,
more robust theoretical predictions of interﬂuorophore distances can be made owing to the
unambiguous site of dye-labeling aﬀorded by chemoselective thiol-maleimide conjugation and
greatly simpliﬁes FRET data interpretation. In this case, the system could be treated as centro-
symmetric with dyes equidistantly arranged around a central QD donor, with the FRET equation
reducing to:
E =
nR60
nR60 + r6
where n is the number of acceptors surrounding the donor [3]. In addition, the lower molecular
weight of the truncated antibody conjugate (7 nm Ö 5 nm Ö 4nm) could aﬀord higher dye:QD
stoichiometries owing to enhanced steric accessibility compared to the larger full length antibody.
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Figure 4.15: Time-resolved photoluminescence decays of Abl kinase reactions (200 mU/µl) using
Alexa Fluor 647 maleimide labeled antibody Fab' fragments (c.a. 50:1 Fab':QD).
F(ab')2 were generated by partial enzymatic digestion with Ficin - a cysteine protease derived
from ﬁg latex - which preferentially cleaves the Fc hinge region and the thiols reduced and
modiﬁed with the maleimide derivative of Alexa Fluor 647. These fragments were then utilised
in QD kinase activity assays for Abl (500 mU/µl) in an analagous manner to the full-length
IgG, and the time-resolved photoluminescence decays were recorded to detect FRET. The decay
times in the absence and presence of Fab' or where a non-phosphorylatable Y/F substitution
peptide was used did not provide any evidence for changes in donor lifetime suggesting that
FRET was not an active process. Indeed, the observed decays were superimposable, giving
average τ of 16.8 ± 0.8 ns (Figure 4.15). This could be due to the antibody binding site being
compromised following the dye labeling procedure due to the extended period spent at elevated
temperature during protelytic generation of the Fab' fragment. Owing to limiting amounts of
material and with the possibility that the approach may be intrinsically unfeasible, the use of
Fab' fragments as immunodetection reagents in the assay was not investigated further.
Whilst it may be possible to produce similar ﬂuorophore-antibody conjugates of well-deﬁned
structure, it should be emphasised that enzymatic means of preparation involve extensive pro-
cessing, puriﬁcation and have limited throughput. In summary, although there are beneﬁts in
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having reduced ambiguity in the conjugate structure, this must be weighed against potential
limitations associated with relative ease of conjugate preparation. For example, it should be
possible to site-selectively label the Fc region of the phosphotyrosine antibodies by targeting
carbohydrate moieties with hydrazide-modiﬁed acceptor dyes [124]. Although this should not
compromise the antigen binding site the integrity of the antibody's antigen binding site, this
would presumably result in the FRET acceptor dyes being oriented relatively far from the QD
donor and may preclude eﬃcient energy transfer.
4.4 Conclusions and Further Work
Quantum dots coated with judiciously designed peptide sequences can serve as surrogate sub-
strates in a new protein kinase activity assay based on immunorecognition-actuated FRET and
can be applied to screening potential enzyme inhibitors. The assay is simple and does not re-
quire the need for sophisticated instrumentation. In principle, the luminescent readout of the
system could be readily tailored by simply changing the D-A FRET pair to suit the user -
for example, NIR emitting QDs/dyes should further provide a means to limit autoﬂuorescence
interference. The strong distance dependence of FRET prevents unbound antiphosphotyrosine
antibodies from contributing to the measured signal and aﬀords convenient homogeneous reac-
tions. Whilst the dimensions of most antibodies are large relative to distances associated with
high-eﬃciency FRET regimes [145], the eﬃcient FRET (76%) observed here can be attributed
to several design features. Namely, the small-hydrodynamic radius of the peptide-QD conju-
gate aﬀorded by self-assembly assists in minimising D-A distance separation, QD-dye D-A pairs
can exhibit relatively large Förster radii [46] and each quantum dot is capable of binding to
multiple antibodies, permitting a high overall dye: QD ratio. It may be possible to further
increase the maximum FRET eﬃciency by increasing dye loading on the antibody and inves-
tigating other QD-acceptor pairs which exhibit larger Förster radii [48]. This could facilitate
the use of larger full-length His6-appended recombinant protein substrates, as opposed to syn-
thetic peptides, as although they would more accurately mimic endogenous protein substrates,
their larger relative size would result in an increase in the distance of closest approach between
the QD donor and dye acceptors. In addition, the antibody dye-label could be substitute for
a lanthanide cryptate to allow the QD to serve as an energy transfer acceptor as opposed to
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donor to enable time-resolved measurements and further assist in temporal discrimination of
background signal [51]. This approach should also provide a convenient means of harnessing the
multiplexing capabilities of QDs. This would be of particular use in the context of discovery of
selective kinase inhibitors and would provide a means to assay two or more enzymes simulta-
neously in an individual reaction. For example, two or more QDs with well-separated emission
wavelengths could be conjugated to distinct substrate peptides for kinases with non-overlapping
substrate speciﬁcity followed by phosphorylation in the presence of the respective kinases. A
generic phosphoamino acid antibody could then be added to the system, itself conjugated to a
europium or terbium cryptate, and allowed to bind to the phosphorylated peptides. Subjecting
this heterogeneous population to an excitation pulse, followed by a time delay and subsequent
measurement of QD photoluminescence should result in the observation long-lifetime energy
transfer from the cryptate to the QD, with the respective QD emission intensities corresponding
to the relative degree of phosphorylation of the distinct QD-peptide conjugates [69].
In principle, provided the availability of appropriate antibodies, it should be possible to
extend the assay principle to other kinases, including serine/threonine kinases [107]. This work
is currently being built upon by applying the assay to the detection of other medically relevant
kinases, speciﬁcally the catalytic domain of the human epidermal growth factor receptor 2
(HER2) - commonly mutated or overexpressed in breast and lung cancer [199] - in order to
determine its utility as a potential diagnostic tool in a multiplexed kinase/protease assay.
As kinase assays are often carried out in crude cell lysates in drug discovery applications
[200][107], it would be interesting to test the QD-based assay in a similar context to further
validate its applicability as a pharmaceutical screening tool. An intriguing potential applica-
tion of this QD-kinase sensing approach would be its utility in measuring kinase activity within
live cells. This would necessitate the development of suitable strategies to deliver QD-peptide
substrates and/or antibodies to the cytosol and thus presents a signiﬁcant challenge. This
could be realised using various methods developed for gene transfection based on the use of
cationic polymers, cell-penetrating peptides, surfactants, liposomes or electroporation to deliver
macromolecule payloads within the cell by providing a mechanism to pass through the plasma
membrane or escape endosomal pathways [142]. Nonetheless, successful and stable delivery of
both QD and antibody to the cell followed by an enzyme-dependent FRET response would
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likely require substantial modiﬁcations to the system in consideration of the protein-rich and
complicated milieu of the intracellular environnment. For instance, the propensity for peptide
dissociation from the nanocrystal surface, proteolytic cleavage or non-speciﬁc binding may pro-
vide sources of complication to intracellular enzyme sensing [201]. An initial proof-of-concept
study could involve the optimisation of QD-substrate peptide delivery to kinase (+) and kinase
(-) cells, followed by ﬁxation of the cells and immunostaining with a FRET-acceptor labeled
anti-phosphoamino acid antibody and FRET-based immunodetection by standard ﬂuorescence
microscopy. Although this procedure would not provide a route to live-cell imaging, this exper-
iment would provide valuable insight into whether the QD-peptides have biological activity in
an intracellular environment and can be acted upon a cognate kinase in a physiological context.
An important limitation of the assay here is its dependence on the use of potentially expen-
sive antibodies. It may be possible to substitute antibodies with other possible aﬃnity ligands.
For instance, it may be possible to engineer suitable aptamers, metal-chelate based aﬃnity lig-
ands or naturally occuring phosphoresidue binding domains (e.g. SH2 domains) to serve as
speciﬁc phosphorecognition motifs [202]. Another potential antibody-free assay could employ
γ-biotin-ATP, resulting in kinase-mediated biotinylation of the QDs, followed by detection with
a FRET-acceptor labeled streptavidin [203]. In light of the fact that QD photoluminescence is
often critically dependent upon environment and surface ligand chemistry, it may be possible
to exploit the appreciable changes in surface charge upon phosphorylation for an antibody-
free based approach. For example, for some QD compositions, phosphorylation of the peptide
coated-QDs could be manifested as an altered excited-state lifetime, shift in the photolumines-
cence emission maximum or changes in the emission intermittency statistics (i.e. blinking) [66].
Alternatively, many protein kinases can utilise γ-S-ADP as a surrogate co-substrate to substi-
tute for ATP. The use of γ-S-ADP results in enzymatic incorporation of thiol groups into the
target substrate and provides a useful chemical handle for further derivitisation. Such enzymatic
chemical modiﬁcation has been used to incorporate thio-phosphate aﬃnity tags into potential
kinase targets, which are subsequently captured by a thiol-reactive probe to allow phosphopro-
tein enrichment [204]. An analagous approach could be adopted here, whereby the QD-peptide
is enzymatically thiolated and subsequently reacted with a chemically-modiﬁed FRET reporter
dye to aﬀord antibody-free detection.
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An additional limitation of the assay lies in reagent preparation, due to the need for QD-
peptide solubilisation, preparation and puriﬁcation. The ability to use reagents from commercial
sources could simplify the assay, but would require appreciable redesign. For example, it may be
possible to use commercially available streptavidin coated QDs in conjunction with a biotinylated
kinase substrate and lanthanide-labeled anti-phosphoamino acid antibody to avoid the need for
in-house nanoparticle derivitisation.
Finally, these initial results raise the interesting possibility that QDs may be utilised to de-
tect other enzyme-catalysed modiﬁcations distinct from phosphorylation, providing a universal
platform to detect other enzyme activities and related post-translational modiﬁcations. Chapter
5 details another embodiment of this enzye-detection strategy, by applying it to measure the
activity of an unrelated family of enzyme.
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Chapter 5
Quantum Dot Probes for Histone
Acetyl Transferase Activity
5.1 Introduction
Given the demonstration that QDs can be tailored to detect the activity of protein kinases, it
was sought to investigate whether the approach was generalisable and if it could be applied to
detect the activity of unrelated enzymes which mediate post-translational modiﬁcations. This
chapter describes the development of QD systems designed to measure the activity of histone
acetyltransferases (HATs).
HATs catalyse the acetylation of lysine residues of target proteins using acetyl-CoA as an
acyl donor co-substrate (Figure 5.1). This has the eﬀect of neutralising the lysine side chain,
typically cationic at physiological pH, and creates new opportunities for interaction with acetyl-
lysine binding proteins [205]. HATs play a crucial role within the nucleus, where they serve to
preserve the integrity of the genome and provide additional levels of transcriptional regulation
of gene expression [206, 207]. Although the knowledge of the precise DNA base pair sequence
of many genomes has yielded a wealth of powerful evolutionary and functional information
concerning gene function, it is becoming increasingly apparent that this is insuﬃcient to assist
in our comprehensive understaning of how gene expression is regulated in a tightly controlled
temporal and cell-speciﬁc manner [208, 209]. This is of great importance to fully understand
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Figure 5.1: Acetyl-CoA structure and HAT-catalysed acetylation of histone lysine residues
fundamental cellular processes such as development and stem cell diﬀerentiation. In order to
provide such levels of additional regulation, eukaryotic cells employ an elaborate system of
chemical modiﬁcations which act upon DNA itself and a host of proteins which intimately
interact with DNA and have a profound inﬂuence on higher-order DNA structure and gene
expression. These modiﬁcations serve to assist in deﬁning when and to what extent certain
genes are expressed. This functional information encoded by such protein- and DNA-chemical
modiﬁcations is known as epigenetics [210, 211].
The genome of eukaryotic cells is condensed into the nucleus by means of the formation of
protein-DNA interactions mediated by histone proteins to form higher-order structure known
as chromatin. Histones are highly basic proteins consisting of two copies of the core proteins
H2A, H2B, H3 and H4 arranged to form an octameric complex. The individual histone proteins
consist of a globular C-terminal core domain and a ﬂexible lysine-rich N-terminus ('tail') which
protrudes from the core, as revealed in the X-ray crystal structure [212]. 146 base pairs of DNA
are spooled around the nucleosome structure in a left handed superhelix to provide the funda-
mental repeating unit of chromatin structure - the nucleosome core particle (Figure 5.2) - and
additional accessory proteins further facilitate condensation of the DNA. This process results in
a ∼104-fold compaction which must be reconciled with the fact that a multitude of DNA-binding
proteins require unhindered access to their target sequences in order to maintain tight temporal
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Figure 5.2: The nucleosome core particle complexed with DNA (Protein Data Bank code 1AOI)
with N-terminal histone tails protruding from assembly & known mammalian histone tail acety-
lation targets and associated enzymes (adapted from Abcam.com)
regulation of fundamental processes associated with DNA metabolism, such as replication, re-
pair, recombination, transcription and integration of extracellular signals with changes in nuclear
activity. It is now well understood that underlying chromatin structure plays a fundamental
role in the regulation of these processes which, in turn, is determined by precisely controlled
post-translational modiﬁcation of histone side chains. The lysine-rich N-terminal histone tails
are subject to a wide range of reversible modiﬁcations including acetylation, methylation, phos-
phorylation, ubiquitinylation, ADP-ribosylation and SUMOylation (Table 5.1) [213, 209, 214].
These modiﬁcations serve as recruitment sites for a plethora of transcription factors and other
eﬀectors of chromatin structure by means of complementary protein domains which are capable
of recognising speciﬁc side-chain modiﬁcations [215]. The notion that an underlying language
exists which relates combinations of histone modiﬁcations to speciﬁc changes in chromatin struc-
ture and gene expression is known as the histone code hypothesis [208].
There is increasing evidence that histone modiﬁcation and global epigenetic variations may
play a signiﬁcant role in the development of several disease states by means of several potential
mechanisms [221]. For example, trimethylation of lysine 9 of histone 3 (H3K9me3) is typically
associated with the establishment and maintenance of transcriptionally silent heterochromatin
and is essential to preserve genomic integrity. The protein, GASC1, has been found to be over-
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Modiﬁcation Targeted Residues Example Enzymes Known Regulated Functions
Acetylation Lys CBP/P300, PCAF/GCN5 Transcription, Repair, Replication, Condensation
Mono-, di-, tri-methylation Lys, Arg SUV39H1, MLL1 Transcription, Repair
Phosphorylation Ser, Thr CKII, Mst1 Transcription, Repair, Condensation
Ubiquitinylation Lys Bmi/Ring1A, RNF20/RNF40 Transcription, Repair
Sumoylation Lys UBC9 Transcription
ADP-ribosylation Arg, Glu Rt6-1 Transcription
Deimination Arg PADI4 Transcription
Proline Isomerisation Pro ScFPR4 Transcription
Table 5.1: Histone modiﬁcations and targeted residues [213] [216] [217] [218] [219] [220]
expressed in oesophageal squamous cell carcinoma and posesses H3K9me3/H3k9me2 demethy-
lation activity, as observed in vitro and in vivo, and aberrant overactivity may contribute to
derepression of previously silent oncogenes [222]. In addition, mouse models of Huntington's dis-
ease suggest that abberant epigenetic control of transcription plays a role in disease etiology, as
treatment with histone deacetylase (HDAC) inhibitors results in increased histone acetylation in
the brain and correlates with amelioration of disease symptoms [223]. Global analysis of histone
acetylation patterns in prostate cancer cells can also serve as an accurate indicator of disease
prognosis [221]. In addition to cancer, histone acetyl transferases have also been implicated in
chronic inﬂammation, such asthma and chronic obstructive pulmonary disease (COPD) [224].
Finally, integration of HIV-1 genetic material into the human genome, catalysed by the viral
integrase protein (IN), is potentiated by p300-mediated acetylation of conserved lysine residues
within the C-terminal region of IN [225]. Considering the broad disease implications of aber-
rant HAT activity, HATs are an emerging class of drug target and the ability to measure HAT
activity is an obligatory step in the development of new small molecule activity modulators.
5.1.1 HAT assays
Radioisotope labeling techniques using [3H] acetyl-CoA are one of the most widely used methods
used to detect HAT activity owing to the combined beneﬁts of sensitivity and versatility in assay
design. For example, they can be applied to study the acetylation of full length histone substrates
or synthetic peptides followed by separation of the isotope-labeled substrate by means of gel
electrophoresis or ﬁlter binding and quantitation by phosphorimage analysis or scintillation
counting [226]. Owing to the need for additional separatory steps and complications associated
with waste disposal, other colourimetric and ﬂuorometric assays have been developed. For
example, it is possible to convert the HS-CoA by-product generated during the course of the
117
HAT reaction into a colourimetric signal by means of an enzyme coupled reaction generating
reduced NADH and concomitant increased absorption at 340 nm or reacting the HS-CoA with
maleimide derivatives of coumarin dyes to form a ﬂuorescent adduct[227].
In addition to these approaches, there are some reports which make use of nanoparticle-
speciﬁc phenomena to examine histone modiﬁcations. For example, surface enhanced Raman
scattering using silver colloids can be used to detect and discriminate diﬀerent histone tail
modiﬁcations with high-sensitivity (zmol) by means of their distinct associated spectral sig-
natures [228]. This approach was limited to the use of highly puriﬁed peptides prepared by
chemical synthesis and may be unsuitable for analysis of in vitro enzyme reactions, where a
relatively heterogeneous sample composition could complicate peak assignment in the SERS
spectrum. In addition, quantum dots have been applied to screen on-bead peptide libraries
for preferred substrate sequence speciﬁcity of histone deacetylases (HDACs) [229]. Here, a li-
brary of bead-immobilised peptide sequences, each containing an acetyl-lysine residue ﬂanked
by random amino acid residues, was treated with the HDAC SIRT1, leading to the generation
of free lysyl -amino groups. These groups were subsequently detected by modiﬁcation with
NHS-biotin followed by binding to streptavidin-coated QDs. It is possible to envisage how this
approach could be modiﬁed to detect HAT activity (i.e. the antagonistic acetylation enzyme
reaction) and probe substrate speciﬁcity by employing non-acetylated peptides in conjunction
with QDs labelled with an appropriate anti-acetyl-lysine antibody or another suitable aﬃnity
motif. Nonetheless, the heterogeneous nature of this system limits its applicability to high
throughput screening for potential modulators of enzyme activity.
5.1.2 Aims and scope of the chapter
In consideration of the current assay methods, it was sought to adapt the previously described
QD-kinase technology to the detection of HAT activity. The catalytic domain of the transcrip-
tional coactivator p300 was chosen as a model system to develop a new assay for HAT activity
owing to its comprehensive biochemical and structural characterisation and its clinical signif-
icance [230]. It was sought to design and synthesise appropriate peptide substrates for p300,
conjugate these peptides to QDs, and apply the resultant peptide-conjugates to detect HAT
activity in an analagous manner to the previously developed kinase system. This was chosen
118
as to demonstrate that despite the fundamental disparities in enzyme structure, function and
catalytic mechanism between kinases and HATs, the QD assay principle can be readily adapted
to detect the activity of an arbitrary choice of transferase enzyme, providing a potential route
to a universal assay format for transferases which could be rapidly tailored to detect diﬀerent
enzymes by simply modifying the peptide substrate sequence and antibody speciﬁcity. This
chapter details the development of a novel QD-based HAT assay, the initial studies conducted
to develop the HAT sensing system, vital control experiments carried out to guide essential
redesign of the assay format, assay optimisation, further characterisation and demonstration
that QDs can be successfully applied to quantitatively screen for potential inhibitors of HAT
activity.
5.2 Materials and Methods
5.2.1 Peptide synthesis
A hexahistidine-terminate peptide substrate for p300 based on the N-terminal tail sequence of
the H4 protein (H2N-RGKGGKGLGKGAKAHHHHHH-CONH2) was synthesised by HOBt/HBTU
coupling of Fmoc-protected amino acid monomers in NMP using a 10-fold excess of amino acids
per coupling step. The peptide was cleaved from the resin, puriﬁed, lyophilised and charac-
terised by MALDI as described previously. This peptide sequence was derived from residues
4-12 of the N-terminal tail region of H4 and carries all necessary determinants to serve as a
cognate substrate for p300 [231].
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Figure 5.3: HPLC puriﬁcation of the hexahistidine-appended H4 peptide. The single peak
illustrates the high-purity of the product.
5.2.2 Bioconjugate preparation
QDs were rendered water soluble and conjugated to the puriﬁed His6−appended substrate as
described in Chapter 3. Monoclonal anti-acetyl lysine (clone 7F8) was labeled with AlexaFluor
647 - succinimidyl ester as described in Chapter 4.
5.2.3 p300 HAT assay
Stock solutions of the puriﬁed recombinant catalytic domain of p300 (Millipore, MA) were
diluted in assay buﬀer (50 mM Tris-HCl (pH 8.0), 10 % (v/v) glycerol, 0.1% (w/v) BSA) and
incubated with 20 µM H4-tail peptide and 100 µM acetyl-CoA (trilithium salt, Sigma-Aldrich)
in a total volume of 10 µl for 2 hr at 30 0C. A 2 µl aliquot of the reaction mixture was added to
10 µl of a 50 nM QD solution in assay buﬀer to allow peptide self-assembly on the nanocrystal
surface. Steady-state photoluminescence spectra were recorded on a Spectramax M5 microplate
reader (Molecular Devices) using 400 nm excitation.
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5.2.4 Peptide chemical acetylation
Nucleophilic −amino groups of lysine residues, arginine guanidium groups and peptide N-
termini are susceptible to chemical acylation by acetic anhydride [123]. 1 mg of H4-tail peptide
was dissolved in 500 µl of PBS in a glass vial on ice. With continuous mixing provided by
magnetic agitation, a 10-fold excess of acetic anhydride relative to total reactive amine groups
was added in 20 µl aliquots over the course of 15 min and the mixture allowed to stir for 1
hr. The progress of the reaction was monitored by removing aliquots of the reaction, spotting
onto silica-coated thin layer chromatagraphy plates followed by ninhydrin staining to detect the
presence of free amino groups [232]. The acetylated peptide was analysed by MALDI and stored
at 40C without further puriﬁcation.
Figure 5.4: Acetic anhydride histone lysine acetylation
5.2.5 Solid-phase antibody binding assay to acetyl lysine
The lysyl side chains of BSA were acetylated by adding a 20-fold molar excess of acetic anhydride
dropwise to a 10 mg/ml BSA solution in PBS on ice. The mixture was incubated for 2 hr and
used without further puriﬁcation. 40 nm diameter citrate-stabilised gold nanoparticles (500 µl, 1
nM) were coated with acetylated BSA (1 mg/ml) by electrostatic assembly [123] and puriﬁed by
centrifugation (9,000 g, 10 min) and resuspension of the pellet in PBS. Dye-labeled anti-acetyl
lysine antibody was spotted onto a nitrocellulose membrane and free binding sites blocked
with BSA as described in Chapter 3. The membrane was incubated with the Ac-BSA/AuNP
conjugate, diluted in a PBS solution containing 0.1 % (w/v) BSA to a ﬁnal AuNP concentration
of 100 pM for 3 hr at room temperature, followed by extensive washing in PBS and deionised
water and silver enhancement, as described in Chapter 2.
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5.3 Results
5.3.1 Substrate QD conjugation
In order to investigate whether the kinase assay principle could be translated directly to mea-
sure HAT activity, it was sought to conjugate the p300 substrate peptide directly to the QD
surface. Incubation of QD with peptide at peptide:QD ratios 30-50:1 in 50 mM borate buﬀer
(pH 9.6) failed to produce stable QD dispersions, as evident from visible particle ﬂocculation
following centrifugation (13,000 g, 3 min). As the peptide is lysine-rich and has strong cationic
character, it was sought to neutralise the charge density on the peptide by conducting conjuga-
tion reactions (30:1 peptide:QD) at elevated pH using 50 mM NaCO3 (pH 11.0). Under these
conditions, the ability of the peptide to interact with the QD surface electrostatically should be
limited thus favouring hexahistidine binding. These elevated pH conditions were conducive to
stable conjugate formation, as indicated by a lack of pelleting following centrifugation or any
obvious signs of macroscopic aggregation. These conjugates were further analysed by agarose
gel electrophoresis as described (Figure 5.5). It was observed that at elevated peptide:QD ratios
>35:1 were accompanied my marked decrease in photoluminescence intensity. This may reﬂect
a precipitation of the QD material in the gel owing to limited compatibility with gel running
buﬀer and/or the introduction of additional surface-trap states by the cationic peptide [233].
Further evidence was obtained to suggest that lysine reidues were responsible for the diﬃculty
in preparing the QD-conjugates and the observed quenching of photoluminescence by compar-
ing the H4-peptide self-assembly characteristics with those of an acetylated derivative prepared
by prior treatment of the peptide with acetic anhydride. This peptide did not cause macro-
scopic aggregation of QDs and the conjugates did not exhibit any signiﬁcant photoluminescence
quenching. In light of these observations, in summary, a ratio of 40:1 H4-peptide:QD was chosen
to prepare the p300 substrate conjugates. It was essential to conduct the conjugation reactions
at elevated pH to minimise particle ﬂocculation induced by electrostatic charge screening by the
peptide.
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Figure 5.5: Titration and agarose gel electrophoresis of H4 peptide:QD conjugates
5.3.2 p300 HAT assay with QD-peptide conjugates
It was sought to determine whether the generic protein kinase assay protocol could be readily
adapted to assay p300 activity. p300 was incubated with the H4-substrate conjugate in the pres-
ence or absence of 100 µM acetyl-CoA for 2 hr at 300C before addition of a 10-fold molar excess
of AF647-labeled anti-acetyl lysine antibody to QD. Numerous eﬀorts failed to reveal sensitised
AF647 emission and diminished QD donor emission indicative of FRET. This is somewhat sur-
prising, as the overall dimensions of the QD-peptide should be comparable to the physiological
nucleosome core particle from which the histone tails protrude [209]. The failure to observe
evidence for p300 acetyltransferase-dependent FRET could be due to several possible reasons,
for example i) the QD-dye distances are too great to observe FRET; ii) an inactive or insuﬃ-
cent amounts of enzyme limiting the acetylation; iii) non-functional antibody conjugates with
compromised binding sites; iv) the antibody has insuﬃcent accessibility to the QD-immobilised
peptides; v) assay buﬀer interference; vi) lack of suﬃcient enzyme access to the QD-immobilised
substrate. With these situations in mind, several aditional control experiments were performed
to identify the reasons for the lack of observable FRET.
5.3.3 MALDI analysis of enzyme reaction products
In order to verify that the p300 was catalytically active, reaction mixtures containing (20 µM)
H4-peptide and 200 nM p300 in the presence or absence of acetyl-CoA were analysed by MALDI.
123
These experiments conﬁrmed that the synthetic peptide could serve as a substrate for p300 when
free in solution as suggested by the +42 and +48 increase in molecular mass, corresponding
to the acetylation of one or two amine groups respectively (Figure 5.6). Furthermore, these
observations are are in good agreement with other reported MALDI data on p300 acetylation
of H4-related peptides which also [234]. Thus it is possible to conclude that the enzyme is
active, and the peptide can in principle serve as an enzyme substrate despite the presence of
the appending hexahistidine tag. It was not possible to discern the precise sites of acetylation,
however limited proteolysis with trypsin followed by peptide mass mapping could in theory help
identify which lysine residues are taregeted by the enzyme [235].
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Figure 5.6: MALDI analysis of H4 peptide and acetylated derivatives
5.3.4 Antibody binding to acetylated BSA
A convenient and rapid test for functional anti-acetyl lysine binding was also developed to ensure
that the antibody structure had not been compromised following dye modiﬁcation. To this end a
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heterogeneous assay was developed, with serial dilutions of AF647-labeled AcK antibody spotted
onto a nitrocellulose membrane prior to blocking with 4 % (w/v) BSA. 40 nm citrate-stabilised
gold nanoparticles were passivated with acetylated BSA and incubated with the antibody-coated
membranes [123]. Successful binding was revealed following Ag+/hydroquinone silver enhance-
ment in a [anti-AcK]-dependent manner, suggesting that the binding activity of the antibody
had not been compromised (Figure 5.7).
Figure 5.7: Silver-enhancement binding assay for nitrocellulose-bound anti-AcK antibody and
AuNPs coated with acetylated BSA. Duplicate two-fold dilutions of anti-acetyl lysine antibody
(concentrations shown below) were spotted onto a nitrocellulose membrane prior to blocking
of the membrane with BSA. Gold nanoparticles coated with acetylated BSA were incubated
with the membrane to allow antibody capture. This was followed by extensive washing and
subsequent nucleation of silver salt reduction on the surface-bound gold nanoparticles.
5.3.5 Anti-AcK binding to Ac-H4 peptide modiﬁed QDs
With the suggestion that the anti-AcK antibody had not lost its binding capacity, further
controls were carried out to investigate whether the antibody was compatible with binding to
chemically-acetylated peptides bound to QD surfaces. Acetic-anhydride modiﬁed peptides were
allowed to self-assemble with QDs, as described, and the conjugates simultaneously separated
from excess peptide and transferred into HAT assay buﬀer by centrifugal ﬁltration. Addition
of AF647-labeled anti-AcK resulted in a concomitant increase and decrease in AF647- and
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QD-specifc emission respectively in a concentration-dependent manner. This behaviour was
not observed in the absence of peptide or where the non-acetylated H4 peptide was employed,
suggesting that speciﬁc immunorecognition of acetyllysine was driving the FRET process. From
the steady-state intensities, a maximum FRET eﬃciency of 53 % was observed which suggested
a possible upper limit to the signal response. In addition, inclusion of acetyl-CoA in the medium
did not have any eﬀect on the observed FRET eﬃciencies, conﬁrming that its presence was not
adversely aﬀecting the integrity of the peptide-QD interaction.
Figure 5.8: Immunorecognition of acetylated peptide drives FRET. The acetic anhydride-treated
peptide was assembled on the surface of the QD followed by addition of FRET acceptor dye-
labeled antibody to achieve diﬀerent QD:antibody stoichiometries. These binding assays were
conducted in the presence of 100 µM acetyl-CoA to verify the coenzyme would not interfere
with peptide assembly or antibody binding.
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5.3.6 Enzyme steric accessibility and assay modiﬁcation
Taken together, the above data suggest that the core components of the system (QD, peptide
and cognate antibody) are individually functional but cannot respond appropriately to drive
p300-dependent FRET, implying that the QD-peptide conjugate may be unable to serve as an
eﬃcacious substrate for the enzyme owing to steric hindrance attributable to the dimensions of
the nanoparticle or excessive amounts of peptide on the surface leading to molecular crowding
[135]. It is also possible that the broad distribution of positive surface potential of p300, as
revealed in the high-resolution crystal structure [230], may result in electrostatic repulsion of
the QD-peptide conjugate preventing the peptides from accessing the substrate binding pocket.
Indeed, electrostatic interactions in enzyme-nanoparticle assemblies have been demonstrated to
be able to play a key role in the augmentation of enzyme-substrate association and catalytic
turnover [121]. Several possible approaches could be taken to remediate the apparent insuf-
ﬁciency in enzyme-substrate accessibility. For example, the peptide loading density could be
reduced further, however this could limit the FRET response and the sensitivity of the system.
It could also be possible to modify the substrate sequence with the incorporation of additional
oligoethylene glycol (OEG) or peptide linker motifs to assist in presenting the peptide target
sequence to the p300 active site. This approach, however, would further increase the interﬂuo-
rophore separation and adversely aﬀect the maximum possible FRET eﬃciency and is limited by
the cost of heterobifunctional OEG reagents [236]. In order to circumvent fundamental redesign
of the peptide substrate sequence, an alternative two-step assay methodology was investigated,
whereby enzymatic peptide acetylation is allowed to occur in solution in the absence of QDs.
Following the reaction, the acetylated peptide products are detected by assembling them upon
the surface of the nanocrystals in the presence of the complementary anti-acetyl lysine antibody,
resulting in immunorecognition and FRET (Figure 5.9). This approach is conducive to both
eﬃcient p300 acetylation and antibody binding as supported by the MALDI an FRET data
respectively.
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Figure 5.9: Modiﬁed enzyme sensing procedure. Peptides are treated with p300 in presence of
acetyl-CoA (i) followed by FRET-based QD immunodetection step (ii)
5.3.7 Multistep reaction procedure
Allowing the enzyme acetylation reaction to occur in a QD-free reaction medium prior to immun-
odetection resulted in FRET signals analagous to those observed in the case of the chemically-
acetylated peptide. This eﬀect was not observed in the case when acetyl-CoA was ommitted
from the reaction mixture, consistent with the hypothesis of p300-dependent acetylation of the
peptides being responsible for FRET. BSA was included in the reaction medium to minimise
non-speciﬁc binding and is commonly used as a buﬀer component in HAT assays [234]. Fur-
thermore, despite the reasonably broad speciﬁcity of p300, BSA does not serve as a suitable
acetylation substrate, as indicated by radioisotope labeling studies, and should not provide a
source of assay interference [237]. It was anticipated that its presence may preclude peptide
binding to the QD surface as it is believed to associate readily with the surface of MPA-capped
nanocrystals by electrostatic interaction [173] [238]. Nonetheless, introduction of an aliquot of
the HAT reaction mixture to a solution of QDs and antibody resulted in a rapid increase in the
FRET ratio (670 nm/605 nm) which eventually reached a maximum value in c.a 30 min (note:
the non-zero t = 0 time point owing to dead-time due to sample loading). Thus it can be tenta-
tively concluded that the BSA does not inhibit peptide self-assembly upon the QD surface and
can be incorporated into the assay medium without undue interference. Control experiments
in the absence of acetyl-CoA were also carried out to verify the speciﬁcity of the process which
did not exhibit the same increase in FRET ratio. These observations suggest that the modiﬁed
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two-step assay format can be applied to detect p300 HAT activity and that enzyme access to
the peptide substrate is severely impaired when bound to the surface of the QD. Whilst a two-
step process avoids problems of steric hindrance, this format imposes some limitations, namely
the increased number of reagent transfer steps renders the assay unsuitable for continous real-
time measurements. Nonetheless, this subtle modiﬁcation allows the use of unbound peptide
substrates which may more accurately mimic the behaviour of biological substrates.
Figure 5.10: Time-resolved evolution of FRET signal following addition of acetylated peptide
In addition, aliquots of the p300 reaction mixture were transferred to QD-antibody detection
solutions at time intervals to monitor the evolution of the FRET signal as a function of enzyme
reaction time (Figure 5.11). No further increases dye-speciﬁc emission were observed at t >
60 min suggesting the reaction had gone to completion. Due to suggestions that the QD-H4
peptide could not serve as an eﬀective surrogate substrate, it was presumed that upon binding of
the peptide to the QD surface the transferase reaction would terminate due to steric hindrance,
providing a convenient method to quench the reaction without need for additional inhibitors or
chemical agents [207].
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Figure 5.11: Photoluminescence emission spectra taken at 15 min intervals post-addition of 320
nM p300. The magnitude of FRET between QD and dye was monitored by taking the ratio of
the emission peaks at 670 nm and 605 nm respectively.
5.3.8 Detection limit
The lower detection limit for p300 was determined to be 600 pM based on the concentration of
enzyme required to produce a signiﬁcant signal over a negative control (Figure 5.12). This was
achieved using extended reaction times (6 hr) and is comparable to other radiometric methods,
which are typically considered to be among the most sensitive detection technologies, such as
liquid and ﬂashplate scintillation (8 nM and 200 pM [239, 240]) . Increasing this detection
limit should be possible by increasing the dye:antibody ratio, thereby increasing the number of
total energy acceptors per QD donor and boosting the maximum possible FRET signal. Unfortu-
nately, dye:antibody ratios c.a. > 3.6 could not be prepared for the monoclonal antiacetyl-lysine
antibody used in this study. In the future, the use of antibodies of diﬀerent clonal origin or
polyclonal antibodies which may be amenable to higher dye-loading capacities could boost this
maximum possible FRET response.
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Figure 5.12: 670 nm /605 nm peak ratios for varying enzyme concentrations. Asterisks indicate
signiﬁcant signal above control (95% conﬁdence level, n=3).
5.3.9 Inhibitor response
It has been suggested that selective blockade of HAT activity, including p300, by small-molecule
modulation may provide new therapeutic strategies for the treatment of a range of disease states
[241] [207]. Anacardic acid, a cell-permeable analog of salicylic acid derived from cashew nut
shell extracts, inhibits p300 HAT both in vitro and in vivo and has been proposed as an anti-
tumour agent [242][243]. Anacardic acid acts as a non-competitive p300 inhibitor, however, the
precise structural basis of inhibition is not currently well understood [241]. To demonstrate that
the p300 assay could be used to screen for inhibitors, the enzyme was pre-incubated with serial
dilutions of anacardic acid predisolved in DMSO prior to addition of non-limiting acetyl-CoA
and detection. Increasing concentrations of anacardic acid were predicted to correlate with a
concomitant decrease and increase in emission intensities at 670 nm and 605 nm respectively
due to reduced acetylation and QD-FRET immunocomplex formation. The measured emission
intensities at 605 nm and 670 nm were used to yield the ratio 670 nm/605 nm and plotted as a
function of anacardic acid concentration (Figure 5.14). Consistent with predictions, this yielded
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the sigmoidal behaviour indicative of an inhibitor dose response curve and an apparent IC50
of 76 µM, corresponding reasonably well with the known IC50 of ∼8.5 µM as determined by
radioisotope labeling [241]. An extensive literature review was unable to retrieve any further
examples of IC50 measurements for further comparison and equipment limitations prevented
further IC50 validation using alternative techniques (e.g. [3H]-AcCoA labeling). Nonetheless,
this data suggests that the p300 QD-FRET assay can be used to measure the potency of selective
inhibitor compounds.
Figure 5.13: Anacardic acid structure
Figure 5.14: Anacardic acid dose response curve. 670 nm /605 nm peak ratios showing eﬀect of
pre-incubation with varying concentrations of inhibitor. The data show a typical dose-response
curve. Each data point represents the average of two independent measurements.
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5.4 Conclusions and Future Work
It has been demonstrated that QD surface chemistry can be tailored to detect histone acetyl
transferase activity, providing further evidence that a diverse range of post-translational mod-
iﬁcations can be interrogated using QD-based approaches. It was sought to demonstrate that
the assay principle reported in Chapter 4 for kinase activity could be readily applied to funda-
mentally unrelated families of enzymes without need for fundamental redesign of the system.
In contrast to the kinase system, QD-peptide conjugates did not appear to serve as suitable
surrogate substrates for the p300 HAT, possibly reﬂecting poorly deﬁned steric requirements of
the enzyme and/or innapropriate peptide orientation on the QD surface. This potential hurdle
was overcome by conducting the p300 HAT assay with the substrate peptide free in solution
in order to ensure uncompromised enzyme accessibility, followed by immobilisation on the QD
surface and FRET-based immunodetection. In fact, this modiﬁed assay approach confers several
advantages to the system in that no puriﬁcation of nanoparticle conjugates is required and a
more physiologically relevant substrate can be used as it is free to diﬀuse in solution. In ad-
dition, no elaborate chemical functionalisation or ﬂuorophore labeling of the peptide substrate
is required. This is particularly notable as ﬂuorophore-labeled peptides may not necessarily
provide accurate mimics of endogenous substrates for histone-modifying enzymes and provide
misleading mechanistic information. For example, new inhibitors for the HDAC SIRT1 identiﬁed
in a high-throughput ﬂuorescence polarization assay were proposed to act as speciﬁc activators
of the enzyme, however recent evidence suggests that the inhibitors interact directly with the
TAMRA-labeled peptide substrate used in the assay [244]. The system developed here has
numerous advantages compared to current state of the art and routine laboratory based HAT
assays in that it does not require the use of radioisotope labels and can be conducted in a sin-
gle homogeneous reaction, making the approach conducive to high throughput drug discovery.
Similar to the protein kinase actvity assay developed in the preceding chapter, the QD HAT
assay is of sensitivity comparable to radiometric assays and can be operated using far-red emit-
ting ﬂuorophores, thus providing a convenient means to circumvent biological or test compound
autoﬂuorescence [50].
Given the combined evidence that QDs can be engineered to detect both kinase and HAT
activity, it is not unreasonable to suggest that other post-translational modiﬁcations could be
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detected using a similar approach, simply by changing the sequence of the peptide substrate
and complementary antibody directed towards the speciﬁc covalent modiﬁcation, (methylation,
ubiquitinylation etc.) [245]. In addition, it would be pertinent to investigate whether the HAT
system developed here could be applied to detect site-speciﬁc modiﬁcations and discriminate be-
tween acetylation sites on diﬀerent lysine residues, as the physiological consequences of histone
modiﬁcation is often closely related to its speciﬁc chemical context. For example, acetylation
of histone 4 (H4) K8 and K16 results in transcriptional activation, whereas acetylation of K5
and K12 induces histone deposition on DNA [214]. This could be achieved using the wide range
of commercially available antibodies speciﬁc to individual histone modiﬁcation sites which are
used widely in cellular epigenetic analysis [210]. Furthermore, it is possible that the antagnos-
tic deacetylase reaction (lysine-Ac  lysine-NH2) catalysed by histone deacetylases (HDACs)
could be probed using an analogous sensing procedure. HDACs are also considered to be highly
promising drug targets for the treatment of a range of diseases and several inhibitor compounds
are currently in clinical trials [246]. Such an HDAC assay could be realised using acetylated
peptides based on histone tail sequences, prepared using standard solid-phase synthesis, and
conjugating to the QD following treatment with a cognate HDAC. HDAC activity would pre-
sumably prevent anti-acetyl lysine binding due to loss of the corresponding antigenic site, leading
to a decrease in the rate of QD-dye FRET.
As evolution has yielded a range of histone modiﬁcation-speciﬁc binding domains, it may
be possible to apply ﬂuorescently-labeled recombinant versions of these domains to substitute
for the use of antibodies in the assay; for example, acetylation-speciﬁc bromodomains [208]. In
addition, using recombinant techniques, it may be possible to engineer speciﬁc residues (e.g.
cys) in the binding domain to aﬀord site-speciﬁc ﬂuorophore labeling and thus better-deﬁned
ﬂuorophore orientation. Highly selective DNA aptamers for acetylated histones have been de-
veloped which can discriminate between diﬀerent acetyl lysine residues with high speciﬁcity and
may provide another alternative to the use of antibodies [247].
It may be possible to realise some form of multiplexed assay for the detection two or more
HAT enzymes in a homogeneous reaction, thus providing a means to screen enzyme-speciﬁc
inhibitors. For example, two HATs with non-overlapping substrate speciﬁcity could be incubated
with appropriate His6-appended peptides in a homogeneous acetylation reaction to yield two
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orthogonal acetylated peptides. This would be followed by self-assembly of the peptides on a
QD FRET donor and detection of the acetylated products using two distinct antibodies with
appropriately high speciﬁcity. FRET detection could be aﬀorded by labeling the two diﬀerent
antibodies with appropriate acceptor dyes with similar absorption proﬁles and well-separated
emission spectra in conjunction with spectral deconvolution.
Further work is now in progress in collaboration with the Imperial College Drug Discovery
Centre to further validate the applicability of this assay as a lead discovery tool in automated
medium- and high-throughput screening, potentially assisting in the identiﬁcation of the next
generation of cancer therapeutics based on targeting epigenetic modiﬁcations.
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Chapter 6
Conclusions and Future Work
By integrating diverse elements of biochemistry, chemistry, pharmacology, materials science and
photonics, this thesis has developed novel enzyme sensing strategies with potential utility as
drug discovery tools, based on the unique plasmonic and photoluminescent properties of gold
and semiconductor nanoparticles. Biofunctionalised nanoparticles were designed to undergo
enzyme-dependent aggregation and participate in biospeciﬁc recognition processes to provide
convenient colourimetric or ﬂuorescence signals as a function of enzyme activity.
Chapter 2 aimed to demonstrate the protein kinase-dependent agglutination of antibody-
modiﬁed gold nanoparticles to create a convenient homogeneous colourimetric assay based on
interparticle plasmon coupling. It was determined that this approach had signiﬁcant technical
limitations due to complicated nanoparticle derivitization protocols, slow binding kinetics and
susceptibility to non-speciﬁc binding. Nonetheless, it was demonstrated that these antibody-
gold nanoparticle immunoconjugates may have utility in simple heterogeneous immunoassays
based on silver enhancement ampliﬁcation.
In order to address the limitations of the gold nanoparticle system, an alternative enzyme
sensing strategy was developed based on energy transfer (FRET) between peptide modiﬁed
quantum dots and dye-labeled antibody molecules. Rather than employing complicated, multi-
step nanoparticle modiﬁcation procedures, reliant upon expensive heterofunctional crosslinkers,
water soluble quantum dots were conjugated to peptides based on known protein kinase sub-
strates using a rapid self-assembly strategy as described in Chapter 3. This is the ﬁrst demon-
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stration that commercially available quantum dots can be rendered water soluble and conjugated
to peptides under mild ambient benchtop conditions and should facilitate the development of
future nanocrystal-biomolecule conjugates. In addition, these peptide-based nanoparticle con-
jugates could also be applied to simple immunoassays for target antigens in a heterogeneous
immunoassay and in vitro imaging. Chapter 4 detailed how these peptide-QD conjugates can
serve as substrates in a simple, generic, sensitive and rapid protein kinase activity assay based
on immunorecognition-actuated FRET between QD-phosphopeptide donors and dye-labeled an-
tiphosphotyrosine antibodies. The assay has signiﬁcant advantages over state of the art ﬂuoro-
metric approaches due to the spectral tunability of the system and myriad of QD-acceptor dye
combinations from which to develop further kinase assays. This system is undergoing further
optimisation and being used as an experimental basis for cellular QD-enzyme assays to distin-
guish between cells expressing a particular kinase and cells in which kinase expression has been
selectively knocked down using RNAi [248].
Chapter 5 sought to extend from this assay principle to gain evidence that it was indeed
generic and could be applied to distinctly unrelated enzyme systems. As a proof of concept,
the assay was tailored to detect an unrelated enzyme family, the histone acetyltransferases
(HATs), an emerging class of drug target candidates, as exempliﬁed by the model enzyme
p300. Initial experiments suggested that peptide-QD conjugates could not serve as eﬃcacious
p300 substrates in a manner analagous to the protein kinase system, possibly reﬂecting poorly-
controlled peptide orientation on the nanocrystal surface or insuﬃcient enzyme accessibility to
the substrate sequence. This issue was circumvented by adapting the HAT assay in a multistep
procedure whereby the enzyme-catalyzed acetylation reaction was initially conducted with the
peptide free to diﬀuse in solution, followed by a detection step involving capture of the acetylated
peptide on the QD surface and antibody-based FRET detection using dye-labeled antiacetyl
lysine antibodies. In addition it is notable that fortuitously, this approach achieved one of
the principle aims of the gold nanoparticle-based enzyme detection approach; namely the use of
peptide substrates which remain unbound from the nanoparticle surface, thereby abrogating the
necessity for complicated nanoparticle derivitisation whilst providing a more accurate mimic of
natural substrates. This QD-based HAT detection approach had sensitivity comparable to state
of the art radioisotope-based procedures, removing the need for costly and potentially hazardous
138
reagents such as scintillant-coated microplates and [3H]-acetyl-CoA [240] [244]. It should be
possible to readily apply this assay to high-throughput screening of small-molecule libraries for
compounds which selectively inhibit p300 activity, thereby providing a new simple lead-discovery
tool for potential therapeutics for diseases such as cancer, HIV and chronic inﬂammation [234,
226, 249]. Subtle modiﬁcation of the system, for instance by changing the peptide substrate
sequence to correspond to diﬀerent histone-tail motifs (i.e. H2A, H2B, H3), should enable
the detection of other related HAT enzymes with diﬀerent substrate speciﬁcity. It is possible
to envisage a highly multiplexed histone tail modiﬁcation assay where four QDs with distinct
emission proﬁles could each be conjugated to one of the four histone tail sequences, followed by
subjecting to enzyme-catalyzed modiﬁcation and detection with appropriate antibodies. This
approach could provide a technique to probe the substrate speciﬁcity of histone modifying
enzymes, however the ability to prepare stable QD-histone tail conjugates which can be readily
accessed by enzymes is a fundamental prerequisite to the realisation of this potentially powerful
yet complex hypothetical system.
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